Uridine triphosphate

An uracil nucleoside.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Natural product

1
Supporting references
0
Contradictory references
8
AI-suggested references
84
Clinical trials

General information

Uridine triphosphate is a natural uracil nucleoside. Its solution in an aerosolized form can be used in diagnostic or as a sputum expectoration drug (NCIt).

Uridine triphosphate on DrugBank
Uridine triphosphate on PubChem
Uridine triphosphate on Wikipedia


Synonyms

UTP

 

Structure image - Uridine triphosphate

C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)OP(=O)(O)OP(=O)(O)O)O)O


Supporting references

Link Tested on Impact factor Notes Publication date
Screening of Therapeutic Agents for COVID-19 Using Machine Learning and Ensemble Docking Studies
Screening
in silico 6.71

Predicted to bind the SARS-CoV-2 spike protein or spike protein:ACE2 interface.

Aug/05/2020

AI-suggested references

Clinical trials

ID Title Status Phase Start date Completion date
NCT04389567 Famotidine Outpatient COVID-19 Treatment Study Completed May/12/2020 May/25/2020
  • Alternative id - 1605914-1
  • Interventions - Drug: Famotidine
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, United States
  • Study designs - Observational Model: Case-Only|Time Perspective: Retrospective
  • Enrollment - 10
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Symptomatic improvement|Peripheral blood oxygen saturation
NCT04363099 Multicentre Observational Study on Management COVID 19 Positive Outpatients in a French Cluster. Recruiting Mar/01/2020 Dec/31/2020
  • Alternative id - 2020-A01059-30
  • Interventions - Other: observational
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Msp de Creil, Creil, France
  • Study designs - Observational Model: Cohort|Time Perspective: Other
  • Enrollment - 1000
  • Age - up to 99 Years   (Child, Adult, Older Adult)
  • Outcome measures - clinical description of covid 19 ambulatory cases.|Biological and radiological description of ambulatory cases|Prevalence of positive cases (PCR and/or serological positive)
NCT04847141 A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients Terminated Phase 3 Apr/28/2021 Dec/27/2021
  • Alternative id - GC2010|2021-000269-34
  • Interventions - Biological: C19-IG 20%|Drug: 0.9% Sodium chloride
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - CAP Gornal, L'Hospitalet de Llobregat, Barcelona, Spain|CAP Navàs, Navàs, Barcelona, Spain|CAP Sant Fèlix, Sabadell, Barcelona, Spain|Centro de Salud Nuestra Señora del Pilar, Alcalá de Henares, Madrid, Spain|Centro de Salud Presentación Sabio, Móstoles, Madrid, Spain|CAP Manso, Barcelona, Spain|CAP Maluquer Salvador, Girona, Spain|Centro de Salud San Andrés, Madrid, Spain|Centro de Salud Fuentelarreina, Madrid, Spain|Centro de Salud Hacienda de Pavones Sureste, Madrid, Spain|Centro de Salud Isla de Oza Noroeste, Madrid, Spain|Hospital Sant Pau i Santa Tecla, Tarragona, Spain
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 465
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Percentage of Asymptomatic Participants who Remain Asymptomatic, i.e., who do not Develop Symptomatic COVID-19|Change from Baseline in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load (log10 copies/mL)|Percentage of Participants who Remain in an Outpatient Setting and Maintain Peripheral Oxygen Saturation by Pulse Oximetry (SpO2) ≥94% on Room Air|Percentage of Participants Negative for SARS-CoV-2 by Polymerase Chain Reaction (PCR)|Time to Negative SARS-CoV-2 PCR|Percentage of Participants who Require Oxygen (O2) Supplementation|Duration of Any Oxygen|Absolute Value Score on a 7-point Ordinal Scale|Mean Change from Baseline in the 7-point Ordinal Scale|Percentage of Participants in Each Severity Category of the 7-point Ordinal Scale|Change from Baseline in National Early Warning Score (NEWS)|Percentage of Participants who Require At Least One COVID-19 Related Medically Attended Visit for Management/Treatment of COVID-19 which may Occur in Any Setting|Percentage of Participants who Require Hospital Admission for Medical Care (Non-Quarantine Purposes)|Duration of Hospital Stay|Percentage of Participants who Require Intensive Care Unit (ICU) Admission or Initiation of ICU Level Care|Duration of ICU Stay|Percentage of Participants Requiring Invasive Mechanical Ventilation|Duration of Invasive Mechanical Ventilation|Number of Participants with All-Cause Mortality|Number of Participants with Critical COVID-19 Illness|Length of Time to Clinical Progression to Critical COVID-19 Illness|Time to COVID-19 Symptoms
NCT04662060 COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol Recruiting Phase 2 Apr/23/2021 Aug/01/2022
  • Alternative id - COPPS-Acebilustat
  • Interventions - Drug: Acebilustat|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Stanford University, Stanford, California, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 120
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - For Clinical Domain: Time-to-sustained-resolution|For the Viral Domain: Change in Viral Shedding|Time to viral cessation|Time to first resolution|Time to full resolution|Indicator of SARS-CoV-2 related hospitalizations, ED visits, or death in outpatients with COVID-19 disease.|Indicator participant has developed antibodies to SARS-CoV-2
NCT04501952 Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting Terminated Phase 3 Sep/18/2020 May/06/2021
  • Alternative id - GS-US-540-9012|2020-003510-12
  • Interventions - Drug: RDV|Drug: Placebo to Match RDV
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Arizona Liver Health, Chandler, Arizona, United States|Arizona Clinical Trials, Tucson, Arizona, United States|St Joseph Hospital Eureka, Eureka, California, United States|St. Joseph Heritage Healthcare, Fullerton, California, United States|Elevated Health, Huntington Beach, California, United States|Ruane Clinical Research Group, Los Angeles, California, United States|LA Universal Center, INC., Los Angeles, California, United States|Mills Clinical Research, Los Angeles, California, United States|Kaiser Permanente Northern California, Oakland, California, United States|FOMAT Medical Research, Oxnard, California, United States|UC Davis Health, Sacramento, California, United States|Kaiser Permanente Northern California, 6600 Bruceville Road, Sacramento, California, United States|Kaiser Permanente Northern California, 2025 Morse Ave, Sacramento, California, United States|Kaiser Permanente Northern California, 1200 El Camino Real, San Francisco, California, United States|Kaiser Permanente Northern California, 2425 Geary Blvd, San Francisco, California, United States|UCSF Medical Center, San Francisco, California, United States|Kaiser Permanente Northern California, 250 Hospital Parkway, Suite 850, San Jose, California, United States|Kaiser Permanente Northern California, 2500 Merced St, San Leandro, California, United States|St. Joseph Heritage Healthcare, Santa Rosa, California, United States|Premiere Medical Center of Burbank, Inc, Toluca Lake, California, United States|Kaiser Permanente Northern California, 975 Sereno Drive, Vallejo, California, United States|New Hope Research Development DBA HCD, Whittier, California, United States|Centura Health Porter Place, Denver, Colorado, United States|Nuvance Health, Danbury, Connecticut, United States|RecioMed Clinical Research Network, Boynton Beach, Florida, United States|Midland Florida Clinical Research Center, LLC, DeLand, Florida, United States|Invesclinic, Fort Lauderdale, Florida, United States|Lawnwood Regional Medical Center, Fort Pierce, Florida, United States|Evolution Clinical Trials, Hialeah Gardens, Florida, United States|Encore Medical Research, Hollywood, Florida, United States|Advanced Pulmonary Research Institute, Loxahatchee Groves, Florida, United States|L&C Professional Medical Research Institute, Miami, Florida, United States|Laguna Clinical Research Associates, Miami, Florida, United States|CTMD Research, Inc, Palm Springs, Florida, United States|IMIC Inc, Palmetto Bay, Florida, United States|Luminous Clinical Research - South Florida Urgent Care, Pembroke Pines, Florida, United States|St. Josephs Comprehensive Research Institute, Tampa, Florida, United States|AIDS Research and Treatment Center of the Treasure Coast, Vero Beach, Florida, United States|Triple O Research Institute PA, West Palm Beach, Florida, United States|Agile Clinical Research Trials, Atlanta, Georgia, United States|Mercer University School of Medicine, Macon, Georgia, United States|Infectious Disease Associates of Kansas City, P.C.Infectious Disease Associates of Kansas City, P.C., Burr Ridge, Illinois, United States|Metro Infectious Disease Consultants, Burr Ridge, Illinois, United States|NorthStar Medical Center, Chicago, Illinois, United States|NorthShore University Healthsystem, Evanston, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Holy Cross Hospital, Inc., Baltimore, Maryland, United States|University of Maryland Baltimore, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|South Shore Hospital, South Weymouth, Massachusetts, United States|VA Boston Healthcare System, West Roxbury, Massachusetts, United States|Be Well Medical Center, Berkley, Michigan, United States|Onyx Research Institute, Flint, Michigan, United States|Memorial Hospital of Gulfport, Gulfport, Mississippi, United States|Metro Infectious Disease Consultants, Kansas City, Missouri, United States|Quality Clinical Research Inc., Omaha, Nebraska, United States|AB Clinical Trials, Las Vegas, Nevada, United States|AXCES Research Group, Santa Fe, New Mexico, United States|New York Presbyterian Hospital, Flushing, New York, United States|Northwell Health, New Hyde Park, New York, United States|Atrium Health Carolinas Medical Center, Charlotte, North Carolina, United States|East Carolina University, Greenville, North Carolina, United States|Rosedale Infectious Diseases, Huntersville, North Carolina, United States|Christ Hospital, Cincinnati, Ohio, United States|Cherokee Nation WW Hastings Hospital, Tahlequah, Oklahoma, United States|Providence St. Vincent Medical Center, Portland, Oregon, United States|Temple University, Philadelphia, Pennsylvania, United States|Avera Research Institute, Sioux Falls, South Dakota, United States|University of Tennessee Health Science Center, Knoxville, Tennessee, United States|Central Texas Clinical Research, Austin, Texas, United States|UT Physicians, Bellaire, Texas, United States|Baylor University Medical Center, 700 Scott and White Dr., College Station, Texas, United States|Baylor University Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Care United Research, LLC, Forney, Texas, United States|VIP Trials, Harlingen, Texas, United States|University of Texas, Houston, Texas, United States|The Crofoot Research Center, Inc, Houston, Texas, United States|Baylor University Medical Center, 1901 North McArthur Blvd, Irving, Texas, United States|Laguna Clinical Research Associates, Laredo, Texas, United States|Diagnostic Clinic of Longview - Center for Clinical Research, Longview, Texas, United States|STAAMP Research, San Antonio, Texas, United States|Sugar Lakes Family Practice, Sugar Land, Texas, United States|Baylor University Medical Center, 2201 MacArthur Dr., Suite 100, Waco, Texas, United States|ClinPoint Trials, Waxahachie, Texas, United States|Intermountain Healthcare, Murray, Utah, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Sound Medical Research, Port Orchard, Washington, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Providence Medical Research Center, Spokane, Washington, United States|Wisconsin Corporation for Biomedical Research, Milwaukee, Wisconsin, United States|Aalborg University Hospital, Aalborg, Denmark|Aarhus University Hospital, Aarhus N, Denmark|Rigshospitalet, Copenhagen, Denmark|Hvidovre Hospital, Hvidovre, Denmark|Odense University Hospital, Odense, Denmark|Hospital Universitari Germans Trias i Pujol, Badalona, Spain|Hospital Clinic, Barcelona, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Bradford Teaching Hospitals NHS Foundation Trust, Bradford, United Kingdom|University College Hospital, London, United Kingdom|St Mary's Hospital, London, United Kingdom|Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 584
  • Age - 12 Years and older   (Child, Adult, Older Adult)
  • Outcome measures - Percentage of Participants With Coronavirus Disease 2019 (COVID-19) Related Hospitalization (Defined as at Least 24 Hours of Acute Care) or All-Cause Death by Day 28|Percentage of Participants Who Experienced Treatment-Emergent Adverse Events (TEAEs)|Percentage of Participants With COVID-19 Related Medical Visits Attended in Person by the Participant and a Health Care Professional (MAVs) or All-Cause Death by Day 28|Percentage of Participants Who Died by Day 28|Percentage of Participants With COVID-19 Related Hospitalization at Day 28|Percentage of Participants With COVID-19 Related Hospitalization or All-Cause Death by Day 14|Percentage of Participants With COVID-19 Related MAVs or All-Cause Death by Day 14|Time-Weighted Average Change in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Viral Load From Baseline to Day 7|Time to Alleviation (Mild or Absent) of Baseline COVID-19 Symptoms as Reported on the COVID-19-adapted Influenza Patient-Reported Outcome Plus Questionnaire (FLU-PRO Plus)|Percentage of Participants With Worsening After Alleviation of Baseline COVID-19 Symptoms as Reported on the COVID-19-adapted FLU-PRO Plus Questionnaire|Percentage of Participants Who Required Oxygen Supplementation by Day 28
NCT04779346 Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Disease (COVID-19) in the Oncology Outpatient Setting Recruiting Dec/21/2020 Dec/31/2022
  • Alternative id - 2020-10275-BO-ff
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 500
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Rate of SARS-CoV-2 antibody positive patients|Rate of SARS-CoV-2 antibody positivity after 3, 6, 9, 12 months in previously SARS-CoV-2 antibody positive patients|Rate of SARS-CoV-2 antibody positivity after 3, 6, 9, 12 months in previously SARS-CoV-2 vaccinated patients|Rate of unknown prior COVID19 disease in SARS-CoV-2 antibody positive patients|Rate of cancer entities in SARS-CoV-2 antibody positive patients|Rate of therapy modalities in SARS-CoV-2 antibody positive patients|Subgroup analysis of SARS-CoV-2 antibody positivity after 3, 6, 9, 12 months in previously SARS-CoV-2 vaccinated patients|Rate of re-infection in SARS-CoV-2 antibody positive patients
NCT04456049 Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-19 Not yet recruiting Phase 2 Jul/01/2020 Dec/01/2021
  • Alternative id - COVID_ENZA
  • Interventions - Drug: Enzalutamide
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Oncology Institute of Southern Switzerland (IOSI), Bellinzona, Switzerland
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 90
  • Age - 50 Years and older   (Adult, Older Adult)
  • Outcome measures - Efficacy of Enzalutamide|Disease progression|Tollerability of Enzalutamide
NCT04530474 Outpatient Use of Ivermectin in COVID-19 Withdrawn Phase 3 Apr/01/2021 Jun/30/2021
  • Alternative id - 1285242
  • Interventions - Drug: Ivermectin Pill|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Temple University Hospital, Philadelphia, Pennsylvania, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Clinical Improvement
NCT04466540 Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19) Completed Phase 4 May/12/2020 Sep/28/2021
  • Alternative id - 30415320.8.1001.0070
  • Interventions - Drug: Hydroxychloroquine|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Centro de Pesquisas Clínicas Dr. Marco Mota HCOR, Maceió, Alagoas, Brazil|Hospital e Clínica São Roque, Ipiaú, Bahia, Brazil|Clínica Otorhinus, Salvador, Bahia, Brazil|Hospital da Bahia, Salvador, Bahia, Brazil|Hospital Santa Izabel, Salvador, Bahia, Brazil|Instituto Cárdio Pulmonar da Bahia, Salvador, Bahia, Brazil|Hospital SAMUR, Vitória Da Conquista, Bahia, Brazil|Hospital Maternidade São Vicente de Paulo, Barbalha, Ceará, Brazil|Hospital Unimed Cariri, Juazeiro Do Norte, Ceará, Brazil|Unimed Sul Capixaba, Cachoeiro De Itapemirim, Espírito Santo, Brazil|Hospital das Clínicas Universidade Federal de Goiás, Goiânia, Goiás, Brazil|Santa Casa de Misericórdia de Passos, Passos, Minas Agerais, Brazil|Hospital Júlia Kubitschek, Belo Horizonte, Minas Gerais, Brazil|Instituto da Pequenas Missionárias de Maria Imaculada - Hospital Madre Teresa, Belo Horizonte, Minas Gerais, Brazil|Casa de Caridade de Carangola, Carangola, Minas Gerais, Brazil|Hospital Maternidade e Pronto Socorro Santa Lucia, Poços De Caldas, Minas Gerais, Brazil|Hospital da Unimed, São João Del Rei, Minas Gerais, Brazil|Santa Casa de Misericórdia de São João Del Rei, São João Del Rei, Minas Gerais, Brazil|Hospital de Clínicas da Universidade Federal do Triangulo Mineiro, Uberaba, Minas Gerais, Brazil|Hospital de Clínicas da Universidade Federal de Uberlândia, Uberlândia, Minas Gerais, Brazil|Hospital do Rocio, Campo Largo, Paraná, Brazil|Clínica Clinilive, Maringá, Paraná, Brazil|Hospital Universitário Regional de Maringá, Maringá, Paraná, Brazil|PROCAPE, Recife, Pernambuco, Brazil|Real Hospital Português de Beneficência em Pernambuco, Recife, Pernambuco, Brazil|SECRETARIA MUNICIPAL DE SAÚDE DE SAIRÉ (Unidade Mista Olília Mendonça Souto Maior), Sairé, Pernambuco, Brazil|Complexo Hospitalar de Niterói, Niterói, Rio De Janeiro, Brazil|Hospital Unimed Volta Redonda, Volta Redonda, Rio De Janeiro, Brazil|Associação Dr. Bartholomeu Tacchini, Bento Gonçalves, Rio Grande Do Sul, Brazil|Hospital São Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Santa Casa de Misericórdia de Porto Alegre (ISCMPA), Porto Alegre, Rio Grande Do Sul, Brazil|Universidade Federal de Santa Maria, Santa Maria, Rio Grande Do Sul, Brazil|CEPEM Centro de Pesquisa de Medicina Tropical de Rondônia, Porto Velho, Rondônia, Brazil|Irmandade de Misericórdia Do Hospital Da Santa Casa de Monte Alto, Monte alto, Salto Alto, Brazil|Maestri e Kormann Consultoria Medico Cientifica, Blumenau, Santa Catarina, Brazil|Imigrantes Hospital e Maternidade, Brusque, Santa Catarina, Brazil|Hospital São José, Criciúma, Santa Catarina, Brazil|Hospital Regional Hans Dieter Schmidt, Joinville, Santa Catarina, Brazil|Santa Casa de Araras, Araras, São Paulo, Brazil|Hospital de Amor, Barretos, São Paulo, Brazil|Santa Casa de Misericórdia de Barretos, Barretos, São Paulo, Brazil|Alphacor Cardiologia Clinica E Diagnóstica LTDA, Barueri, São Paulo, Brazil|Faculdade de Medicina de Botucatu, UNESP, Botucatu, São Paulo, Brazil|Hospital Regional do Litoral Norte, Caraguatatuba, São Paulo, Brazil|Hospital de Cordeirópolis, Cordeirópolis, São Paulo, Brazil|Centro de Combate ao Coronavírus de Itapevi, Itapevi, São Paulo, Brazil|Dux Medicina, Jundiaí, São Paulo, Brazil|Hospital Carlos Fenando Malzoni, Matão, São Paulo, Brazil|Centro de Atendimento Para O Enfrentamento A Covid-19 Da Prefeitura Municipal de Monte Altoprefeitura de Monte Alto, Monte alto, São Paulo, Brazil|Faculdade de Medicina de Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil|Unimed Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil|Hospital Casa de Saúde de Santos, Santos, São Paulo, Brazil|Kaiser Clínica e Hospital Dia, São José Do Rio Preto, São Paulo, Brazil|Hospital Policlin, São José Dos Campos, São Paulo, Brazil|Hospital Regional de São José dos Campos, São José Dos Campos, São Paulo, Brazil|Santa Casa de Misericórdia de Votuporanga, Votuporanga, São Paulo, Brazil|ESF Dr. João Paccola Primo, Lençois Paulista, Brazil|Cardioclinica da Ilha do Governador, Rio De Janeiro, Brazil|International Research Center - Hospital Alemão Oswaldo Cruz, São Paulo, Brazil|Hospital do Coração, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|Hospital Leforte, São Paulo, Brazil|Hospital Moriah, São Paulo, Brazil|Hospital Samaritano, São Paulo, Brazil|Hospital Santa Paula, São Paulo, Brazil|Hospital São Camilo Pompéia, São Paulo, Brazil|Hospital São Paulo - UNIFESP, São Paulo, Brazil|Hospital Sírio-Libanês, São Paulo, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 1372
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Hospitalization|Uncontrolled asthma after ≥ 5 days of starting study medication|Pneumonia|Otitis media|Fever resolution time|Time to improve respiratory symptoms|Hospitalization in the Intensive Care Unit|Need for Orotracheal Intubation|Mechanical Ventilation Time|Mortality
NCT04793243 Vitamin D3 Levels in COVID-19 Outpatients From Western Mexico Completed Not Applicable Aug/17/2020 Oct/24/2020
  • Alternative id - CI-07620
  • Interventions - Dietary Supplement: Vitamin D3
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care
  • Enrollment - 42
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Baseline levels of serum vitamin D in COVID-19 patients|Correlation between D-dimer and vitamin D serum levels in COVID-19 patients|Correlation between transferrin and vitamin D serum levels in COVID-19 patients|Correlation between ferritin and vitamin D serum levels in COVID-19 patients|Effects of vitamin D3 supplementation on COVID-19 patients
NCT04853108 Remote Monitoring of COVID-19 Positive Outpatients Enrolling by invitation Jun/25/2021 Jun/01/2022
  • Alternative id - STUDY00001408
  • Interventions - Other: Remote Monitoring of COVID-19
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Emory Clinic, Emory University Hospital, Atlanta, Georgia, United States
  • Study designs - Observational Model: Case-Only|Time Perspective: Retrospective
  • Enrollment - 500
  • Age - 25 Years to 99 Years   (Adult, Older Adult)
  • Outcome measures - Identify Parameters Associated with Adverse Outcomes|Develop Algorithm for Deterioration
NCT04853134 Proxalutamide Treatment for COVID-19 Female Outpatients Withdrawn Phase 3 Nov/01/2020 Dec/01/2021
  • Alternative id - AB-DRUG-SARS-005
  • Interventions - Drug: Proxalutamide|Other: Standard of Care
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Corpometria Institute, Brasilia, Brazil
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - COVID-19 hospitalization
NCT04545060 VIR-7831 for the Early Treatment of COVID-19 in Outpatients Completed Phase 2|Phase 3 Aug/27/2020 Sep/02/2021
  • Alternative id - VIR-7831-5001|GSK Study 214367
  • Interventions - Biological: VIR-7831|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Investigative Site, Anniston, Alabama, United States|Investigative Site, Cullman, Alabama, United States|Investigative Site, Mesa, Arizona, United States|Investigative Site, Tucson, Arizona, United States|Investigative Site, Los Angeles, California, United States|Investigative Site, Los Angeles, California, United States|Investigative Site, Northridge, California, United States|Investigative Site, Oxnard, California, United States|Investigative Site, Rolling Hills Estates, California, United States|Investigative Site, Sacramento, California, United States|Investigative Site, Doral, Florida, United States|Investigative Site, Gainesville, Florida, United States|Investigative Site, Hialeah, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miami, Florida, United States|Investigative Site, Miramar, Florida, United States|Investigative Site, North Miami, Florida, United States|Investigative Site, Palmetto Bay, Florida, United States|Investigative Site, Pembroke Pines, Florida, United States|Investigative Site, Pompano Beach, Florida, United States|Investigative Site, Tampa, Florida, United States|Investigative Site, Tampa, Florida, United States|Investigative Site, Atlanta, Georgia, United States|Investigative Site, Atlanta, Georgia, United States|Investigative Site, Decatur, Georgia, United States|Investigative Site, Stockbridge, Georgia, United States|Investigative Site, Idaho Falls, Idaho, United States|Investigative Site, Mishawaka, Indiana, United States|Investigative Site, Lake Charles, Louisiana, United States|Investigative Site, Marrero, Louisiana, United States|Investigative Site, Baltimore, Maryland, United States|Investigative Site, Caro, Michigan, United States|Investigative Site, Hazelwood, Missouri, United States|Investigative Site, Las Vegas, Nevada, United States|Investigative Site, Las Vegas, Nevada, United States|Investigative Site, Santa Fe, New Mexico, United States|Investigative Site, Bronx, New York, United States|Investigative Site, Asheboro, North Carolina, United States|Investigative Site, Charlotte, North Carolina, United States|Investigative Site, Columbus, Ohio, United States|Investigative Site, Smithfield, Pennsylvania, United States|Investigative Site, Chattanooga, Tennessee, United States|Investigative Site, Austin, Texas, United States|Investigative Site, Baytown, Texas, United States|Investigative Site, Beaumont, Texas, United States|Investigative Site, Denton, Texas, United States|Investigative Site, El Paso, Texas, United States|Investigative Site, Forney, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, Houston, Texas, United States|Investigative Site, Humble, Texas, United States|Investigative Site, Laredo, Texas, United States|Investigative Site, McAllen, Texas, United States|Investigative Site, Mesquite, Texas, United States|Investigative Site, Sugar Land, Texas, United States|Investigative Site, Kirkland, Washington, United States|Investigative Site, Seattle, Washington, United States|Investigative Site, Vienna, Austria|Investigative Site, Vienna, Austria|Investigative Site, Belo Horizonte, Minas Gerais, Brazil|Investigative Site, Maringá, Parana, Brazil|Investigative Site, Natal, Rio Grande Do Norte, Brazil|Investigative Site, Passo Fundo, Rio Grande Do Sul, Brazil|Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Investigative Site, Porto Alegre, Rio Grande Do Sul, Brazil|Investigative Site, Chapecó, Santa Catarina, Brazil|Investigative Site, Santo André, Sao Paulo, Brazil|Investigative Site, Vila Assuncao, Sao Paulo, Brazil|Investigative Site, Campinas, São Paulo, Brazil|Investigative Site, Sarnia, Ontario, Canada|Investigative Site, Toronto, Ontario, Canada|Investigative Site, Québec, Quebec, Canada|Investigative Site, Bellavista, Callao, Peru|Investigative Site, El Agustino, Lima, Peru|Investigative Site, Huaral, Lima, Peru|Investigative Site, San Isidro, Lima, Peru|Investigative Site, Bella Vista, Peru|Investigative Site, Lima, Peru|Investigative Site, Terrassa, Barcelona, Spain|Investigative Site, Albacete, Spain|Investigative Site, Centelles, Spain|Investigative Site, Girona, Spain|Investigative Site, Granada, Spain|Investigative Site, Granada, Spain|Investigative Site, Vigo, Spain|Investigative Site, Belfast, United Kingdom
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 1057
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Proportion of participants who have progression of COVID-19 through Day 29|Occurence of of adverse events (AEs)|Occurrence of serious adverse events (SAEs)|Occurrence of adverse events of special interest (AESI)|Incidence and titers (if applicable) of serum ADA to VIR-7831|Cmax|Clast|Tmax|Tlast|AUCinf|AUClast|%AUCextrap|t1/2|Vz|Vss|CL|Proportion of participants who have progression of COVID-19 through Day 29 as defined by visit to a hospital emergency room for management or illness, or hospitalization for acute management of illness or death|Mean change in FLU PRO Plus total score comparing Vir 7831 vs Placebo (AUC through Day 7) and time to symptom alleviation using the FLU-Pro Plus|Change from baseline in viral load in nasal secretions by qRT-PCR at Day 8|Proportion of participants who progress to develop severe and/or critical respiratory COVID-19 as manifest by requirement for and method of supplemental oxygen at Day 8, Day 15, Day 22 or Day 29|29-day, 60-day, and 90-day all-cause mortality
NCT04728919 Nasal and Pulmonary Nitric Oxide Output in COVID-19 Infection Active, not recruiting Jan/15/2021 Jan/15/2024
  • Alternative id - R200090
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Tampere University Hospital, Tampere, Finland
  • Study designs - Observational Model: Case-Control|Time Perspective: Prospective
  • Enrollment - 82
  • Age - 18 Years to 70 Years   (Adult, Older Adult)
  • Outcome measures - Viral load of SARS-CoV-2 from different sample sites|Upper respiratory tract viruses|FeNO|FnNO|Change in FeNO|CHange in FnNO|Airway resistance at 20Hz, R20|Airway resistance at 5Hz, R5|Airway resistance at 20 Hz, R20|Change in R20|Change in R5|Reactance at 5Hz (X5)|Change in X5|Resonant frequency (Fres)|Change in Fres|Reactance area (AХ)|Change in AX|FEV1|FVC|VC|FEV1/FVC|FEV1/VC
NCT04545008 Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19 Terminated Phase 1 Oct/20/2020 Jun/02/2021
  • Alternative id - Pro00100394
  • Interventions - Drug: Famotidine|Drug: N-Acetyl cysteine
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Prisma Health Baptist Easley Hospital, Easley, South Carolina, United States|Prisma Health Greenville Memorial Hospital, Greenville, South Carolina, United States|Prisma Health Greer Memorial Hospital, Greer, South Carolina, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 2
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v5.0|Rate of Hospitalization|Time to Symptom Resolution
NCT04801056 Study of TB006 in Outpatient Patients With Mild to Moderate COVID-19 Withdrawn Phase 1 May/01/2021 Sep/01/2021
  • Alternative id - TB006C1101
  • Interventions - Drug: TB006|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Treatment emergent adverse events|Pharmacokinetic parameters of TB006: AUC(0-last)|Pharmacokinetic parameters of TB006: Cmax|Pharmacokinetic parameters of TB006: Tmax|Pharmacokinetic parameters of TB006: T1/2|Immunogenicity|Preliminary Efficacy: Viral shedding change|Preliminary Efficacy: Viral shedding change at each visit|Preliminary Efficacy: Time to viral shedding clearance|Preliminary Efficacy: Proportion of treated patients with ≥ 1 COVID-19 related medically-attended visit through Day 28|Preliminary Efficacy: Total number of COVID-19 related medically-attended visits|Preliminary Efficacy: Proportion of treated patients admitted to a hospital due to COVID-19|Preliminary Efficacy: Time to sustained clinical recovery from baseline|Preliminary Efficacy: Clinical improvement from baseline at each visit through Day 28 (in patients with or without underlying comorbidities
NCT05156645 A Study to Evaluate Efficacy and Safety of the Combination of SCTA01 & SCTA01C in Outpatients With COVID-19 Withdrawn Phase 1|Phase 2 Jan/15/2022 Dec/01/2022
  • Alternative id - SCTA01/SCTA01C-A301
  • Interventions - Drug: SCTA01 and SCTA01C|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Proportion of participants who experience COVID-19 related hospitalization (defined as at least 24 hours of acute care) or death (all cause) up to Day 29 (Phase III)|Proportion of patients with ≥Grade 3 treatment related adverse event (TRAE) up to Day 8 (Phase I/II)|Time to sustained resolution of all COVID-19-related symptoms|Change in symptom score (total of ratings)|Time to symptom improvement|Proportion of participants that achieve SARS-CoV-2 clearance in NP or OP samples|Immunogenicity assessment includes the number and percentage of patients who develop detectable anti drug antibody|Mean concentration-time profiles of SCTA01 and SCTA01C
NCT04338074 TXA and Corona Virus 2019 (COVID19) in Outpatients Terminated Phase 2 Jun/01/2020 Apr/21/2021
  • Alternative id - TXACOVID1
  • Interventions - Drug: Tranexamic acid tablets|Drug: Placebo oral tablet
  • Study type - Interventional
  • Study results - Has Results
  • Locations - University of Alabama at Birmingham, Birmingham, Alabama, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 5
  • Age - 19 Years and older   (Adult, Older Adult)
  • Outcome measures - Hospitalization
NCT04353284 Camostat Mesylate in COVID-19 Outpatients Completed Phase 2 Jun/09/2020 Apr/22/2021
  • Alternative id - 2000027971
  • Interventions - Drug: Camostat Mesilate|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Yale University, New Haven, Connecticut, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 74
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Change in SARS-COV-2 viral load|Change in positive COVID-19 status|Change in COVID-19 symptom severity|Change in COVID-19 symptom frequency|Change in body temperature
NCT04476602 Ambulatory Management of Moderate to High Risk COVID-19 (SARS-CoV-2) Patients - The Coronavirus Related Outpatient Work Navigators (CROWN) Protocol Recruiting Apr/27/2020 Dec/31/2020
  • Alternative id - 20-0618
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - 410 Lakeville Road, Suite 107, New Hyde Park, New York, United States
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 500
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Hospital Admission
NCT04530617 Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients Terminated Phase 2 Oct/05/2020 Jun/10/2021
  • Alternative id - 3421
  • Interventions - Drug: Camostat Mesilate|Drug: Artemisia Annua Leaf
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, None - Non-US/Canada, Mexico
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 246
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Rate of hospitalizations and oxygen use
NCT04542044 Evaluation of the Safety and Outcomes of Outpatient Management With Mild to Moderate COVID-19 Pneumonia Completed Apr/02/2020 Jun/30/2020
  • Alternative id - CCER2020-01518
  • Interventions - Other: management strategy of outpatient with mild to moderate SARS-CoV-2 pneumonia
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Geneva University Hospital, Geneva, Switzerland
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 40
  • Age - 18 Years to 99 Years   (Adult, Older Adult)
  • Outcome measures - Secondary hospitalization(s) or death COVID-19 related|severity of COVID-19 disease|patient satisfaction with management strategies|Saved costs
NCT04518410 ACTIV-2: A Study for Outpatients With COVID-19 Recruiting Phase 2|Phase 3 Aug/19/2020 Dec/31/2023
  • Alternative id - A5401/ACTIV-2|38742
  • Interventions - Biological: bamlanivimab|Drug: Placebo (IV)|Biological: BRII-196/BRII-198|Biological: AZD7442 (IV)|Biological: AZD7442 (IM)|Drug: SNG001|Drug: Camostat|Drug: Placebo (IM)|Drug: Placebo (Inhaled solution)|Drug: Placebo (oral tablet)|Biological: BMS-986414 + BMS-986413|Drug: Placebo (SC injections)|Biological: SAB-185 (3,840 Units/kg)|Biological: SAB-185 (10,240 Units/kg)|Drug: CASIRIVIMAB + IMDEVIMAB
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Pinnacle Research Group (Site 1082), 321 E. 10th Street, Anniston, Alabama, United States|North Alabama Research Center LLC (Site 1194), 721 W. Market St., Ste. B, Athens, Alabama, United States|University of Alabama at Birmingham (Site 1005), 908 20th Street South, Birmingham, Alabama, United States|Cullman Clinical Trials (Site 1140), 501 Clark St. NE., Cullman, Alabama, United States|Jasper Summit Research, LLC. (Site 1056), 1280 Summit, Jasper, Alabama, United States|Absolute Clinical Research, LLC. (Site 1186), 7725 North 43rd Avenue, Ste. 211, Phoenix, Arizona, United States|University of Arizona (Site 1043), 1501 N. Campbell Ave., Rm. 6410, Tucson, Arizona, United States|Omnibus Clinical Research (Site 1253), 3340 W. Ball Road, Ste. I, Anaheim, California, United States|Franco A. Felizarta MD (Site 1174), 3535 San Dimas St., Bakersfield, California, United States|Clearview Medical Research LLC. (Site 1251), 2714 Hidaway Ave., Ste. 103, Canyon Country, California, United States|St. Jude Heritage Medical Group (Site 1093), 2151 N. Harbor Blvd., Fullerton, California, United States|University of California San Diego (Site 1160), 9350 Campus Point Drive, Perlman Cancer Cancer, La Jolla, California, United States|Fadi A. Haddad, MD, Inc. (Site 1146), 8860 Center Dr., Ste. 320, La Mesa, California, United States|Atella Clinical Research (Site 1111), 5451 La Palma Avenue, La Palma, California, United States|Loma Linda University Health (Site 1110), 11374 Mountain View, Dover Bldg, Ste. C, Loma Linda, California, United States|University of Southern California (Site 1057), 1300 N. Mission Rd., Rm 349, Los Angeles, California, United States|UCLA CARE Center (Site 1003), 11075 Santa Monica Blvd., Suite 100, Los Angeles, California, United States|Science 37, Inc. (Site 1124), 12121 Bluff Creek Dr., Ste. 100, Los Angeles, California, United States|VA Northern California Health Care System (NAVREF) (Site 1137), 10535 Hospital Way, Mather, California, United States|Central Valley Research, LLC (Site 1085), 400 E. Orangeburg Ave., Ste. 5, Modesto, California, United States|Hoag Memorial Hospital Presbyterian (Site 1200), 1 Hoag Dr., Newport Beach, California, United States|Valley Clinical Research, Inc. (Site 1059), 18433 Roscoe Blvd., Ste 210, Northridge, California, United States|University of California Irvine (Site 1083), 843 Health Sciences Road, Orange, California, United States|FOMAT Medical Research (Site 1136), 300 South A Street, Oxnard, California, United States|Eisenhower Medical Center (Site 1040), 39000 Bob Hope Drive, Rancho Mirage, California, United States|Paradigm Research (Site 1150), 3652 Eureka Way, Redding, California, United States|Riverside Medical Clinic (Site 1232), 7117 Brockton Ave., Riverside, California, United States|University of California Davis Medical Center (Site 1097), 2315 Stockton Blvd., Sacramento, California, United States|Premier Urgent Care Centers of California, Inc. (Site 1176), 284 E. Highland Ave., San Bernardino, California, United States|University of California San Diego (Site 1002), 220 Dickinson Street, San Diego, California, United States|Zion Medical Center (Site 1063), 4647 Zion Avenue, San Diego, California, United States|VA San Diego Health System (Stie 1127), 3350 La Jolla, San Diego, California, United States|University of California San Francisco (Site 1009), 995 Potrero Ave., Building 80, Ward 84, San Francisco, California, United States|San Francisco Research Institute (Site 1210), 2435 Ocean Ave., San Francisco, California, United States|Stanford University (Site 1213), 1201 Welch Road, Stanford, California, United States|Millennium Clinical Trials (Site 1260), 550 Saint Charles Dr., Ste. 208, Thousand Oaks, California, United States|Office of Ramesh V. Nathan, MD (Site 1073), 2220 Lynn Rd., Ste. 301, Thousand Oaks, California, United States|Harbor UCLA (Site 1022), 1124 West Carson Street, Torrance, California, United States|Allianz Research Institute Inc. (Site 1159), 14120 Beach Blvd., Ste. 101, Westminster, California, United States|University of Colorado (Site 1007), 12401 East 17th Avenue, Aurora, Colorado, United States|UConn - Institute for Collaboration on Health (Site 1169), 2006 Hillside Rd., Unit 1248, Storrs, Connecticut, United States|Whitman-Walker Health (Site 1027), 1337 R Street NW., Washington, District of Columbia, United States|Imagine Research of Palm Beach County (Site 1157), 709 S. Federal Hwy., Ste. 2, Boynton Beach, Florida, United States|Bradenton Research Center Inc. (Site 1109), 3924 9th Ave. W, Bradenton, Florida, United States|Synergy Healthcare (Site 1099), 300 Riverside Drive E., Ste. 1350, Bradenton, Florida, United States|Cardiology Physicians, P.A. (Site 1180), 305 Memorial Medical Pkwy., Ste. 301, Daytona Beach, Florida, United States|Midland Florida Clinical Research Center LLC (Site 1130), 665 Peachwood Drive, DeLand, Florida, United States|Integrity Clinical Research (Site 1214), 3901 NW 79th Ave., Doral, Florida, United States|Universal Axon Clinical Research (Site 1077), 3650 NW 82nd Ave., Doral, Florida, United States|EMINAT Research (Site 1202), 2500 E. Commercial Blvd., Fort Lauderdale, Florida, United States|Holy Cross Health (Site 1072), 4725 North Federal Highway, Fort Lauderdale, Florida, United States|North Florida / South Georgia Veterans Health System (Site 1133), 1601 SW Archer Rd., Gainesville, Florida, United States|University of Florida (Site 1047), 1600 SW. Archer Rd., Gainesville, Florida, United States|NW FL Clinical Research Group, LLC. (Site 1046), 400 Gulf Breeze Parkway, Gulf Breeze, Florida, United States|Indago Research and Health Center (Site 1050), 3700 W. 12th Ave., Ste. 300, Hialeah, Florida, United States|AGA Clinical Trials (Site 1026), 900 West 49th Street, Hialeah, Florida, United States|Community Research of South Florida (Site 1197), 7100 W. 20th Ave., Ste. 403, Hialeah, Florida, United States|New Generation Medical Research (Site 1204), 7600 W. 20th Ave., Ste. 106, Hialeah, Florida, United States|Best Quality Research, Inc. (Site 1237), 2387 W. 68th St., Ste. 403, Hialeah, Florida, United States|Innovative Health Medical Center (Site 1222), 6750 Taft Street, Hollywood, Florida, United States|University of Florida Jacksonville (Site 1039), 655 West 8th Street, Jacksonville, Florida, United States|Mayo Clinic Jacksonville (Site 1149), 4500 San Pablo Rd. S., Jacksonville, Florida, United States|QC Trials (Site 1117), 300 W. 41st Street, Ste. 203, Miami Beach, Florida, United States|Lakes Research (Site 1037), 5801 NW 151 Street, Miami Lakes, Florida, United States|Savin Medical Group, LLC. (Site 1212), 5789B NW. 151st Street, Miami Lakes, Florida, United States|Amber Clinical Research, LLC. (Site 1206), 9000 NE. 2nd Avenue, Miami Shores, Florida, United States|Gonzalez MD & Aswad MD Health Services (Site 1238), 3401 NW. 7th Street, Miami, Florida, United States|Clintex Research Group, Inc. (Site 1231), 590 SW. 27th Ave., Miami, Florida, United States|Advance Medical Research Center (Site 1193) 330 SW. 27th Ave., Ste. 701, Miami, Florida, United States|University of Miami Miller School of Medicine CoVID Unit (Site 1068), 1425 NW. 10th Ave., Miami, Florida, United States|Florida International Medical Research (Site 1239), 1890 S. Red Rd., Ste. 103, Miami, Florida, United States|D&H National Research Centers (Site 1205), 8485 Bird Road, Miami, Florida, United States|Allied Biomedical Research Institute (Site 1227), 7100 SW. 47th St., Ste. 220, Miami, Florida, United States|Miami Clinical Research (Site 1089), 2400 SW. 69th Ave., Miami, Florida, United States|Research Institute of South Florida, Inc. (Site 1201), 9835 SW. 72nd Street, Ste. 201, Miami, Florida, United States|RM Medical Research, Inc. (Site 1230), 10346 W. Flagler St., Miami, Florida, United States|Pro Live Medical Research Corp (Site 1219), 12781 SW. 42nd Street, Miami, Florida, United States|Miami Dade Medical Research Institute, LLC (Site 1223), 8955 SW. 87th Ct., Miami, Florida, United States|Bravo Health Care Center (Site 1221), 1440 79 Street, North Bay Village, Florida, United States|Orlando Immunology Center (Site 1045), 1707 North Mills Avenue, Orlando, Florida, United States|Clintheory (Site 1203), 7350 Sandlake Commons Blvd., Orlando, Florida, United States|IMIC, Inc. (Site 1141), 18320 Franjo Rd, Palmetto Bay, Florida, United States|Family Clinical Trials (Site 1236), 1601 N. Palm Ave., Ste. 102, Pembroke Pines, Florida, United States|Physician Care Clinical Research, LLC. (Site 1242), 1617 S. Tuttle Ave., Ste. 1A, Sarasota, Florida, United States|Bassetti Medical Research, Inc. (Site 1158), 5825 US Highway 27 N., Sebring, Florida, United States|DBC Research (Site 1188), 7707 N. University Dr., Ste. 106, Tamarac, Florida, United States|ETNA Medical Center (Site 1225), 7401 N. University Drive, Tamarac, Florida, United States|Moore Clinical Research, Inc. (Site 1164), 4257 W. Kennedy Blvd., Tampa, Florida, United States|Tampa General Hospital Family Care Center Healthpark (Site 1088), 5802 N. 30th Street, Tampa, Florida, United States|Infectious Disease Consultants of the Treasure Coast (Site 1171), 3735 11th Cir., Ste. 201, Vero Beach, Florida, United States|AIDS Research and Treatment Center of the Treasure Coast (Site 1095), 981 37th Place, Vero Beach, Florida, United States|Triple O Research Institute PA (Site 1121), 2580 Metrocentre Blvd., Ste. 4, West Palm Beach, Florida, United States|The Ponce de Leon Center (site 1015), 341 Ponce De Leon Avenue Northeast, Atlanta, Georgia, United States|Rare Disease Research, LLC. (Site 1248), 1891 Howell Mill Rd.NW, Ste. B, Atlanta, Georgia, United States|Agile Clinical Rsearch Trials, LLC (Site 1051), 750 Hammond Drive, Atlanta, Georgia, United States|Balanced Life Health Care Solutions/SKYCRNG (Site 1191), 2033 Buford Hwy., Ste. 109, Buford, Georgia, United States|IACT Health (Site 1035), 800 Talbotton Road, Columbus, Georgia, United States|Clintheory (Site 1254), 4300 Pleasant Hill Road, Duluth, Georgia, United States|One Health Research Clinic, Inc. (Site 1250), 5880 Live Oak Pkwy, Ste. 160, Norcross, Georgia, United States|Renew Health Clinical Research, LLC. (Site 1161), 1550 Janmar Rd., Snellville, Georgia, United States|John A. Burns School of Medicine UH Clinics at Kakaako (Site 1177), 651 Ilalo St., Honolulu, Hawaii, United States|Snake River Research, PLLC (Site 1120), 2900 Cortez Ave., Idaho Falls, Idaho, United States|Metro Infectious Disease Consultants (Site 1106), 901 McClintock Dr., Ste. 201, Burr Ridge, Illinois, United States|Chicago Clinical Research Institute (Site 1132), 611 W. Roosevelt Rd., Chicago, Illinois, United States|Northwestern University (Site 1025), 645 North Michigan Ave, Chicago, Illinois, United States|Rush University Medical Center (Site 1017), 600 Paulina St., Chicago, Illinois, United States|University of Illinois at Chicago (Site 1147), 835 South Wood Street, Chicago, Illinois, United States|University of Chicago (Site 1064), 5841 S. Maryland Ave., Chicago, Illinois, United States|Great Lakes Clinical Trials (Site 1049), 5149 N. Ashland Ave., Chicago, Illinois, United States|Investigators Research Group, LLC. (Site 1170), 321 E. Northfield Dr., Ste. 100, Brownsburg, Indiana, United States|Roudebush VA Medical Center (Site 1217), 550 University Blvd, Indianapolis, Indiana, United States|University of Kansas Medical Center (Site 1042), 3901 Rainbow Boulevard, Kansas City, Kansas, United States|MedPharmics (Site 1065), 3800 Houma Blvd., Metairie, Louisiana, United States|Clinical Trials of America, LLC. (Site 1245) 3201 Armand Street, Monroe, Louisiana, United States|New Orleans Adolescent Trials Unit (Site 1028), 1440 Canal St., Suite 904, New Orleans, Louisiana, United States|Louisiana State University Health Sciences Center (Site 1153), 2000 Canal Street, New Orleans, Louisiana, United States|Ochsner Clinic Foundation (Site 1218), 1514 Jefferson Highway, New Orleans, Louisiana, United States|Baltimore VA Medical Center (Site 1258), 10 N. Greene St., Baltimore, Maryland, United States|Johns Hopkins University (Site 1006), 1830 East Monument Street, Baltimore, Maryland, United States|Walter Reed Army Institute of Research (Site 1118), 503 Robert Grant Ave., Silver Spring, Maryland, United States|Massachusetts General Hospital (Site 1016), 55 Fruit Street, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center (Site 1166), 110 Francis Street, Boston, Massachusetts, United States|Brigham and Women's Hospital - Therapeutics Clinical Research Site (Site 1023), 75 Francis Street, Boston, Massachusetts, United States|University of Massachusetts Medical School (Site 1054), 55 Lake Avenue N., Worcester, Massachusetts, United States|Vida Clinical Studies (Site 1244), 3815 Pelham Street, Dearborn, Michigan, United States|Revive Research Institute (Site 1257), 32255 Northwestern Hwy., Farmington Hills, Michigan, United States|Revival Research Corporation (Site 1256), 13409 East 14 Mile Road, Sterling Heights, Michigan, United States|Memorial Hospital at Gulfport (Site 1104), 4500 13th Street, Gulfport, Mississippi, United States|MedPharmics, LLC. (Site 1032), 15190 Community Rd., Gulfport, Mississippi, United States|University of Missouri Health Care System (Site 1224), 1 Hospital Drive, Columbia, Missouri, United States|Hannibal Clinic (Site 1129), 100 Medical Drive, Hannibal, Missouri, United States|Washington University School of Medicine (Site 1008), 620 South Taylor, Suite 200, Saint Louis, Missouri, United States|Bozeman Health Deaconess Hospital (Site 1115), 931 Highland Blvd, Ste. 3103, Bozeman, Montana, United States|Mercury Street Medical Group (Site 1074), 300 W. Mercury St., Butte, Montana, United States|Quality Clinical Research (Site 1112), 10040 Regency Circle, Omaha, Nebraska, United States|Las Vegas Medical Research (Site 1048), 8530 W. Sunset Rd., Las Vegas, Nevada, United States|AXCES Research Group (Site 1152), 531 Harkle Road, Santa Fe, New Mexico, United States|Bronx Prevention Research Center (Site 1108), 390 East 158th Street, Bronx, New York, United States|Lincoln Hospital (Site 1092), 249 East 149th Street, Bronx, New York, United States|Urban Health Plan, Inc. (Site 1243), 1065 Southern Blvd, Bronx, New York, United States|Jacobi Medical Center (Site 1105), 1400 Pelham Parkway South, Bronx, New York, United States|James J. Peters VA Medical Center (Site 1053), 130 West Kingsbridge Road, Bronx, New York, United States|Maimonides Medical Center (Site 1138), 4802 10th Avenue, Brooklyn, New York, United States|University at Buffalo, Emergency Medicine (Site 1172), 77 Goodell Street, Buffalo, New York, United States|Flushing Hospital Medical Center (Site 1067), 4500 Parsons Blvd, Flushing, New York, United States|Jamaica Hospital Medical Center (Site 1066), 8900 Van Wyck Expressway, Jamaica, New York, United States|Columbia Partnership for Prevention and Control of HIV/AIDS CTU (Site 1019), Columbia University Irving Medical Center, Department of Medicine - Division of Infectious Diseases, 180 Fort Washington Avenue, HP6 - Rm 604, New York, New York, United States|Cornell Clinical Trials Unit (Site 1011), NewYork-Presbyterian Hospital-Weill Cornell Medical Center, 525 East 68th Street, New York, New York, United States|Canton-Potsdam Hospital (Site 1076), 50 Leroy Street, Potsdam, New York, United States|University of Rochester (Site 1010), 601 Elmwood Ave, Rochester, New York, United States|SUNY Stony Brook NICHD (Site 1094), HSC L-02, Rm. 142 C, Stony Brook, New York, United States|University of North Carolina at Chapel Hill (Site 1001), 130 Mason Farm Rd., Bioinformatics Bldg, 2nd Floor, Chapel Hill, North Carolina, United States|Carolina Clinical Research (Site 1167), 9040 Nations Ford Rd., Charlotte, North Carolina, United States|Research Carolina Elite (Site 1247), 7480 Waterside Loop Road, Suite 201, Denver, North Carolina, United States|Duke University Medical Center (Site 1041), 40 Duke Medicine Circle, Durham, North Carolina, United States|Carteret Medical Group, LLC. (Site 1249), 302 Medical Park Ct., Morehead City, North Carolina, United States|Wake Forest University Health Sciences (Site 1038), 1 Medical Center Boulevard, Winston-Salem, North Carolina, United States|Sanford Health (Site 1084), 801 Broadway N., Fargo, North Dakota, United States|The Christ Hospital (Site 1119), 2123 Auburn Avenue, Cincinnati, Ohio, United States|Case Western Reserve University (Site 1033), 2061 Cornell Road, Cleveland, Ohio, United States|MetroHealth Medical Center (Site 1195), 2500 Metrohealth Dr., Cleveland, Ohio, United States|Ohio State University Medical Center (Site 1020), 480 Medical Center Drive, Columbus, Ohio, United States|Cincinnati CRS (Site 1004), University of Cincinnati, University Hospital, 200 Albert Sabin Way, Ohio City, Ohio, United States|STAT Research (Site 1107), 66 Remick Blvd., Springboro, Ohio, United States|Ascension St. John Clinical Research Institute (Site 1090), 1725 East 19th Street, Tulsa, Oklahoma, United States|Providence Portland Medical Center (Site 1098), 4805 NE. Glisan Street, Portland, Oregon, United States|Kaiser Permanente Center for Health Research (Site 1079), 3800 N. Interstate Ave., Portland, Oregon, United States|Portland VA Medical Center (Site 1131), 3710 SW US Veterans Hospital Rd., Portland, Oregon, United States|Oregon Health and Science University (Site 1259), 3181 SW. 10th Avenue, Portland, Oregon, United States|Doylestown Hospital (Site 1122), 595 W. State Street, Doylestown, Pennsylvania, United States|University of Pennsylvania (Site 1031), 3400 Spruce Street, Philadelphia, Pennsylvania, United States|The University of Pittsburgh (Site 1018), 3471 5th Ave., Pittsburgh, Pennsylvania, United States|Veterans Affairs Pittsburgh Healthcare System (Site 1070), University Drive C., Pittsburgh, Pennsylvania, United States|The Miriam Hospital Clinical Research Site (1142), 164 Summit Avenue, Providence, Rhode Island, United States|Medtrial, LLC (Site 1134), 1718 Saint Julian Pl., Ste. 2, Columbia, South Carolina, United States|Clinovacare Medical Clinical Research Center (Site 1211), 160 Medical Circle Suite D, West Columbia, South Carolina, United States|American Indian Clinical Trials Research Network (Site 1148), 717 Meade Street, Rapid City, South Dakota, United States|Sanford USD Medical Center (Site 1078), 1305 W. 18th St., Sioux Falls, South Dakota, United States|Clinical Trials Center of Middle Tennessee (Site 1183), 100 Covey Drive, Franklin, Tennessee, United States|Vanderbilt Therapeutics Clinical Research (Site 1013), Vanderbilt Health One Hundred Oaks, 719 Thompson Ln., Ste 47183, Nashville, Tennessee, United States|Saint Hope Foundation Inc. (Site 1100), 6800 West Loop Street, Ste. 560, Bellaire, Texas, United States|South Texas Medical Research Institute, Inc./TTS Research (Site 1198), 1420 River Road, Boerne, Texas, United States|PanAmerican Clinical Research, LLC. (Site 1069), 1416 Palm Blvd., Brownsville, Texas, United States|Trinity Health and Wellness Center (Site 1030), 219 Sunset Avenue, Dallas, Texas, United States|UT Southwestern HIV/ID Clinical Trials Unit (Site 1208), 1936 Amelia Court, Dallas, Texas, United States|Doctors Hospital at Renaissance Health Institute for Research and Development (Site 1145), 5323 S. McColl Rd., Edinburg, Texas, United States|Sealy Institute for Vaccine Sciences Clincial Trials Program (Site 1044), 400 Harborside Drive, Galveston, Texas, United States|Rheumatology Center of Houston (Site 1252), 1200 Binz St., Ste. 1495, Houston, Texas, United States|Lyndon B. Johnson Hospital (Site 1014), 5656 Kelley Street, Houston, Texas, United States|University of Texas Health Science Center at Houston (Site 1055), 6431 Fannin Street, Ste. 2.112, Houston, Texas, United States|Houston Methodist Hospital (Site 1123), 6565 Fannin Street, Houston, Texas, United States|Dynamic Medical Research Group (Site 1081), 8314 Southwest Fwy, Houston, Texas, United States|Fairway Medical Clinic (Site 1156), 4910 Telephone Road, Houston, Texas, United States|Houston Heart and Vascular Associates (Site 1215), 1485 FM 1960 Bypass R. E., Ste. 100, Humble, Texas, United States|SMS Clincial Research, LLC. (Site 1060), 1210 N. Galloway Ave., Mesquite, Texas, United States|Epic Medical Research, LLC (Site 1233), 106 Plaza Drive, Red Oak, Texas, United States|San Antonio Military Medical Center (Site 1173), 3551 Roger Brooke Dr., San Antonio, Texas, United States|Inova Fairfax Medical Campus (Site 1029), 3300 Gallows Road, Falls Church, Virginia, United States|Clinical Research Partners LLC (Site 1196), 7110 Forest Ave., Ste. 201, Richmond, Virginia, United States|EvergreenHealth (Site 1080), 12040 NE 128th Street, Ste MS-77, Kirkland, Washington, United States|University of Washington ACTU (Site 1012), Harborview Medical Center, 325 9th Ave., Seattle, Washington, United States|Providence Medical Research Center (Site 1075), 105 W. 8th Ave., Ste. 6050W, Spokane, Washington, United States|Hershel Woody Williams VA Medical Center (Site 1128), 1540 Spring Valley Drive, Huntington, West Virginia, United States|West VA University, Mary Babb Randolph Cancer Center (Site 1178), 1 Medical Center Drive, Morgantown, West Virginia, United States|Vida Clinical Studies (Site 1246), 5757 West Oklahoma Avenue, Milwaukee, Wisconsin, United States|Medical College of Wisconsin, Inc. (Site 1036), 8701 Watertown Plank Road, Milwaukee, Wisconsin, United States|Allegiance Research Specialists (Site 1162), 2645 N. Mayfair Rd., Ste. 200, Wauwatosa, Wisconsin, United States|Instituto Médico Platense (Site 3011), Avenida 51 335, La Plata, Buenos Aires, Argentina|Fundación Sanatorio Güemes (Site 3001), Francisco Acuña de Figueroa 1240, Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina|Instituto Médico Río Cuarto (Site 3005), Hipólito Yrigoyen 1020, Río Cuarto, Córdoba, Argentina|Instituto Médico de la Fundación Estudios Clínicos (Site 3009), Italia 428, Rosario, Santa Fe, Argentina|Clínica Adventista Belgrano (Site 3007), Estomba 1710, Ciudad Autonoma de Buenos Aires, Argentina|Instituto Ave Pulmo (Site 3006), Carlos M. Alvear 3345, Mar Del Plata, Argentina|Hospital Universitario Austral (Site 3004), Av. Juan Domingo Peron, Derqui, Pilar, Argentina|L2 Ip - Instituto de Pesquisas Clinicas Ltda (Site 4008), SGAS 613, Conjunto E, Lote 95, Sala 6, Brasília, Distrito Federal, Brazil|Hospital Das Clinicas Da Universidade Federal de Minas Gerais (Site 4001), Avenida Alfredo Balena 190, Belo Horizonte, Minas Gerais, Brazil|SOM Federal University Minas Gerais Brazil (Site 4002), Avenida Alfredo Balena 190, Belo Horizonte, Minas Gerais, Brazil|Hospital Nossa Senhora da Conceicao (Site 4004), Avenida Francisco Trein 596, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Dia do Pulmão (Site 4007), Rua Engenheiro Paul Werner, 1141, Blumenau, Santa Catarina, Brazil|Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto (Site 4003), Avenida Bandeirantes 3900, Campus Universitário, Ribeirão Preto, São Paulo, Brazil|Instituto de Pesquisa Clínica Evandro Chagas (Site 4005), Avenida Brasil, 4365, Rio De Janeiro, Brazil|Hospital E Maternidade Celso Pierro (Site 4006), Avenue John Boyd Dunlop S/n, São Paulo, Brazil|Medical Arts Health Research Group (Site 2003), 360-1855 Kirschner Rd., Kelowna, British Columbia, Canada|Vancouver ID Research and Care Centre Society (Site 2006), Infectious Disease Clinic Downtown, Vancouver, British Columbia, Canada|Dr. Anil K. Gupta Medicine Professional Corporation (Site 2004), 1620 Albion Rd., Suite 106, Toronto, Ontario, Canada|Clinica San Agustin Research (Site 9601), Meters West from the National Bank, Desamparados, San José, Costa Rica|Corporacion GIHEMA SA (Site 9602), Carretera Prospero Fernandez, Escazú, Costa Rica|Centro Medico Militar (Site 9401), Finca El Palomar, Acatan, Sta. Rosita Zona 16, Ciudad De Guatemala, Guatemala|CIMAB SA de CV (Site 6002), Francisco I Madero 270 Sur, Torreon, Coahuila, Mexico|Oaxaca Site Management Organization (Site 6004), Calle Humboldt 302, Colonia Centro, Oaxaca, Distrito Federal, Mexico|Instituto Jalisciense de Investigacion Clinica SA de CV (Site 6005), Penitenciaria Numero 20, Colonia Centro, Guadalajara, Jalisco, Mexico|Centro de Investigación Farmacéutica Especializada de Occidente (Site 6006), Av. Vallarta 1670, Piso 2 PH1, Colonia Americana, Guadalajara, Jalisco, Mexico|Neurociencias Estudios Clinicos S.C. (Site 6008), Boulevard Alfonso G. Calderon, 2193 int 2 A desarrollo urbano 3 rios, Culiacán, Sinaloa, Mexico|Hospital Civil De Culiacan (Site 6011), Avenida Álvaro Obregón 1422, Culiacán, Sinaloa, Mexico|Eme Red Hospitalaria (Site 6010), Calle 33 No. 496, Mérida, Yucatán, Mexico|Kohler and Milstein Research (Site 6013), Avenida Colón 197, García Ginerés, Mérida, Yucatán, Mexico|De La Salle Health Sciences Institute (Site 9504), Gov. Mangubat Avenue, Cavite City, Cavite, Philippines|Makati Medical Center (Site 9502), No. 2 Amorsolo Street, Legaspi Village, Makati City, National Capital Region, Philippines|Asian Hospital and Medical Center (Site 9503), 2205 Civic Drive, Muntinlupa, National Capital Region, Philippines|Puerto Rico AIDS Clinical Trials Unit (Site 1024), Proyecto ACTU Biomedical Building II, San Juan, Puerto Rico|Peermed Clinical Trial Center (Site 9215), Corner of Voortrekker and Monument Roads, Kempton Park, Ekurhuleni, Gauteng, South Africa|Worthwhile Clinical Trials (Site 9214), No. 1 Mowbray Avenue, Benoni, Gauteng, South Africa|The Aurum Institute Tembisa Clinical Research Site (Site 9217), Cnr Flint Mazibuko / Rev RTJ Namane Drive, Johannesburg, Gauteng, South Africa|Roodepoort Medicross (Site 9220), 54 Ontdekkers Road, Johannesburg, Gauteng, South Africa|Soweto ACTG CRS (Site 9203), Chris Hani Road, Johannesburg, Gauteng, South Africa|Helen Joseph Hospital (Site 9201), Perth Road, Johannesburg, Gauteng, South Africa|Setshaba Research Centre (Site 9205), 2088 Block H, Pretoria, Gauteng, South Africa|Into Research (Site 9210), Totius Street, Tshwane, Gauteng, South Africa|Durban International Clinical Research Site (Site 9208), Sidmouth Avenue, Durban, Kwazulu - Natal, South Africa|Welkom Clinical Trial Centre (Site 9211), 189 Power Road, Welkom, Matjhabeng, Free State, South Africa|The Aurum Institute Klerksdorp Clinical Research Center (Site 9204), Corner Margaretha Prinsloo St. and O.R. Tambo St., Klerksdorp, North-West, South Africa|The Aurum Institute Rustenburg Clinical Research Site (Site 9202), 50 Steen St., c/o Pretorius St., Rustenburg, North-West, South Africa|TASK Eden (Site 9218), G, 4 Victoria St., George, South Africa|CLINRESCO, ARWYP Medical Suites (Site 9209), 22 Pine Avenue, Johannesburg, South Africa|Mzansi Ethical Research Centre (Site 9212), 184 Cowen Ntuli Street, Steve Tschwete, Mpumalanga, South Africa|Global Clinical Trials Sunnyside (Site 9216), 175 Steve Biko Street, Pretoria, South Africa
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 8797
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - COVID-19 symptom duration (Phase 2)|Quantification of SARS-CoV-2 RNA (Phase 2)|Proportion of participants with new adverse event (AE) ≥ Grade 3 (Phase 2)|Cumulative incidence of death due to any cause or hospitalization due to any cause (Phase 3)|Proportion of participants with new adverse event (AE) ≥ Grade 3 (Phase 3)|COVID-19 symptom duration (Phase 3)|Quantification of SARS-CoV-2 RNA (Phase 3)|Cumulative incidence of death from any cause or hospitalization due to any cause (Phase 2)|Cumulative incidence of death from any cause, or hospitalization due to any cause related to COVID-19 (Phase 3)|Level of SARS-CoV-2 RNA from NP swabs (Phase 2)|Level of SARS-CoV-2 RNA from NP swabs (Phase 3)|Duration of targeted clinical COVID-19 symptoms (Phases 2 and 3)|COVID-19 symptom severity ranking (Phases 2 and 3)|Proportion of participants with ≥1 worsening symptom of COVID-19 (Phases 2 and 3)|Time to self-reported return to usual health (a) (Phases 2 and 3)|Cumulative incidence of death due to any cause or hospitalization due to any cause (Phases 2 and 3)|Oxygen saturation level (Phases 2 and 3)|AUC of SARS-CoV-2 RNA from site-collected NP swabs (Phase 2)|Incidence of new adverse event (AE) ≥ Grade 2 (Phases 2 and 3)|Incidence of new adverse event (AE) ≥ Grade 3 (Phases 2 and 3)|Time to self-reported return to usual health (b) (Phases 2 and 3)
NCT04384406 COVID-19 Outbreak Consequences for Outpatients Followed in PRM Completed Apr/01/2020 May/09/2020
  • Alternative id - RECHMPL20_0262
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Uh Montpellier, Montpellier, France
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 467
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Proportion of patients necessitating the scheduling of a medical consultation|the reason for this urgent need of a medical consultation|the access to other medical services during the quarantine period|the interruption of home-based rehabilitation services
NCT04355767 Convalescent Plasma in Outpatients With COVID-19 Completed Phase 3 Aug/11/2020 Mar/29/2021
  • Alternative id - C3PO|1OT2HL156812-01
  • Interventions - Biological: Convalescent Plasma|Biological: Saline
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Chandler Regional Medical Center, Chandler, Arizona, United States|Valleywise Health Medical Center, Phoenix, Arizona, United States|UCSD Health La Jolla, La Jolla, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Ronald Reagan UCLA Medical Center, Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|UC Davis Medical Center, Sacramento, California, United States|Stanford University, Stanford, California, United States|Harbor-UCLA Medical Center, Torrance, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|UF Health Shands Hospital, Gainesville, Florida, United States|Jackson Memorial Hospital, Miami, Florida, United States|Grady Memorial Hospital, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Illinois Hospital, Chicago, Illinois, United States|University of Chicago Medical Center, Chicago, Illinois, United States|University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Maine Medical Center, Portland, Maine, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Newton-Wellesley Hospital, Newton, Massachusetts, United States|Baystate Medical Center, Springfield, Massachusetts, United States|University of Michigan University Hospital, Ann Arbor, Michigan, United States|Detroit Receiving Hospital, Detroit, Michigan, United States|Harper University Hospital, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Sinai-Grace Hospital, Detroit, Michigan, United States|Spectrum Health Hospitals Butterworth Hospital, Grand Rapids, Michigan, United States|William Beaumont Hospital, Royal Oak, Michigan, United States|William Beaumont Hospital-Troy, Troy, Michigan, United States|HealthPartners Methodist Hospital, Saint Louis Park, Minnesota, United States|Regions Hospital, Saint Paul, Minnesota, United States|Barnes Jewish Hospital, Saint Louis, Missouri, United States|Cooper University Hospital, Camden, New Jersey, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|University of New Mexico Hospital, Albuquerque, New Mexico, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Duke University Hospital, Durham, North Carolina, United States|Wake Forest Baptist Medical Center, Winston-Salem, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|OSU Wexner Medical Center, Columbus, Ohio, United States|Mercy St. Vincent Medical Center, Toledo, Ohio, United States|Oregon Health & Science University Hospital, Portland, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Temple University Hospital, Philadelphia, Pennsylvania, United States|Einstein Medical Center, Philadelphia, Pennsylvania, United States|UPMC Presbyterian Hospital, Pittsburgh, Pennsylvania, United States|William P. Clements Jr. University Hospital, Dallas, Texas, United States|Ben Taub General Hospital, Houston, Texas, United States|Memorial Hermann Texas Medical Center, Houston, Texas, United States|University of Utah Healthcare, Salt Lake City, Utah, United States|Froedtert Hospital, Milwaukee, Wisconsin, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 511
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of Patients With Disease Progression (Intention-to-treat Population)|Number of Patients With Disease Progression (Per-protocol Population)|Worst Severity Rating on the WHO COVID Ordinal Scale for Clinical Improvement During the 30 Days Following Randomization|Number of Patients With Worsening of Symptoms at Day 15 as a Measure of Time to Disease Progression|Number of Hospital-free Days During the 30 Days Following Randomization|All-cause Mortality
NCT04544176 COVID-19 Risk From Attending Outpatient Radiology Appointments Completed Jan/01/2020 Jan/01/2021
  • Alternative id - 20NS031
  • Interventions - Other: Observational
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Nottingham University Hospitals, NHS Trust, Nottingham, Nottinghamshire, United Kingdom
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 48000
  • Age - 16 Years to 100 Years   (Child, Adult, Older Adult)
  • Outcome measures - A microbiological diagnosis of COVID infection.
NCT04365582 OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome Withdrawn Phase 3 May/07/2020 Apr/19/2021
  • Alternative id - OUTCOV
  • Interventions - Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Lopinavir 200Mg/Ritonavir 50Mg Tab
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 50 Years and older   (Adult, Older Adult)
  • Outcome measures - Hospital admission|Effect of treatment on Death at D20|Effect of treatment on Death at D60|Effect of treatment on Death due to COVID at D20|Effect of treatment on Death due to COVID at D60|Effect of treatment on need for ICU stay at D20|Effect of treatment on need for ICU stay at D60|Effect of treatment on duration of ICU stay at D20|Effect of treatment on duration of ICU stay at D60|Effect of treatment on need of mechanical ventilation at D20|Effect of treatment on need of mechanical ventilation at D60|Effect of treatment on duration of mechanical ventilation at D20|Effect of treatment on duration of mechanical ventilation at D60|Effect of treatment on time to hospitalization at D20|Effect of treatment on time to hospitalization at D60|Effect of treatment on Duration of Hospital stay et D20|Effect of treatment on Duration of Hospital stay et D60|Effect of treatment on Duration of symptoms at D20|Effect of treatment on Duration of symptoms at D60|Incidence of Treatment-Emergent Adverse Events
NCT04937088 Outpatient Liquid Aspirin (OLA) Recruiting Phase 2 Dec/06/2021 Dec/05/2022
  • Alternative id - 1658
  • Interventions - Drug: ASA
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Lsuhsc-No, New Orleans, Louisiana, United States
  • Study designs - Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other
  • Enrollment - 200
  • Age - 40 Years and older   (Adult, Older Adult)
  • Outcome measures - Reduced COVID-19 related hospitalizations
NCT04438057 Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19 Recruiting Phase 2 Aug/12/2020 Aug/12/2021
  • Alternative id - MIDC-CCP
  • Interventions - Biological: CCP
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Metro Infectious Disease Consultants, Burr Ridge, Illinois, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 150
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to Resolution of Symptoms|SAEs within 24 hours of plasma infusion|Decrease in Inflammatory Markers|Hospitalization within 28 days
NCT05125887 Remote Assessment of Outpatient With Severe Acute Respiratory Syndrome (SARS-CoV-2) Not yet recruiting Dec/12/2021 Jun/12/2023
  • Alternative id - 87RI21_0033/Evidence
  • Interventions - Other: Questionnaire
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Médecine Interne A, Limoges, France
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 400
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Medical procedures
NCT04521088 Epidemiological Analysis of Ambulant Patients in a COVID-19 Outpatient Clinic Recruiting Jul/02/2020 Dec/31/2020
  • Alternative id - WI-1252
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Institut für Pneumologie an der Universität zu Köln / Wissenschaftliches Institut Bethanien für Pneumologie e.V., Solingen, Nordrhein-Westfalen, Germany
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 1000
  • Age - Child, Adult, Older Adult
  • Outcome measures - possible risk factors|frequency of positive test results after prescribed protective measures|frequency of positive test results within the family or other social groups|number of COVID-19 tests in the outpatient clinic
NCT04803227 Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19 Terminated Phase 1 Mar/11/2021 May/28/2021
  • Alternative id - EMR-COV-PR001|www.pacestudies.com
  • Interventions - Drug: Emricasan|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - SUNY Downstate Health Sciences University, Brooklyn, New York, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 13
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Patient reported outcomes as assessed by COVID-19 assessment tool|Number of participants that experience death during the study.|Number of participants the experience a related serious adverse event as assessed by CTCAE v5.0.|Number of participants that experiences a Grade 3 and 4 adverse event as assessed by CTCAE v5.0|Number of participants with a discontinuation or temporary suspension of study drug|Each participant will be tested for SARS-CoV-2 viral eradication via a sample from the nasopharynx and the sample will be tested via RT- PCR.|Each participant will perform a 6 minute walk test (6MWD) for distance (400-700m) walked.|Each participant will be assessed for COVID-19 severity via an 8-point ordinal scale|Each participant will be tested for anti-SARS-CoV-2 neutralizing antibodies via standard histogram, 2D plots, tSNE, and viSNE analysis.|Each participant will be tested for anti-SARS-CoV-2 quantitative antibodies via cytokine test panel.|Each participant will be assessed for resolution of COVID19 symptoms via performance of hematology and biochemistry labs, SARS-COV-2 nasopharyngeal swab and tested via RT-PCR and immunology testing for cytokines and cell populations.
NCT04934202 Cohort Follow-up of Survivors of Hospitalization for COVID-19 During the 2nd Wave of the Epidemic in France Recruiting May/05/2021 May/05/2022
  • Alternative id - COMEBAC 2
  • Interventions - Other: Teleconsultation|Other: Outpatient clinic
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Bicetre hospital, Le Kremlin-Bicêtre, France
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 500
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Prevalence of respiratory, cognitive and psychological symptoms presented at 6 months of hospitalization for COVID-19.|Difference between the prevalence of residual symptoms between patients hospitalized during the 1st wave of the epidemic in France (from the COMEBAC "1st wave" study) and those of the current study|Association between patient characteristics and the prevalence of residual symptoms.|Association between residual symptoms and the type of SARS-CoV-2 variant|Prevalence of respiratory, neurological, cognitive and psychological symptoms presented at 6 months of hospitalization for COVID-19 which occurred during the 1st epidemic wave.
NCT04402905 Observational Study in Diagnosed Patients COVID-19, Supported on an Outpatient Basis. (COVID-PSL) Completed Jun/15/2020 Aug/15/2020
  • Alternative id - CREPATS 011
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Yasmine Dudoit, Paris, France
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 450
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - COVID-PSL Cohort
NCT04839107 Institutional Registry on Outpatient and Hospitalized COVID-19 Infected Patients Recruiting Apr/14/2020 Dec/31/2021
  • Alternative id - 5604
  • Interventions -
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Hospital Italiano, Caba, Ciudad Autónoma De Buenos Aires, Argentina
  • Study designs - Observational Model: Cohort|Time Perspective: Other
  • Enrollment - 20000
  • Age - 18 Years to 100 Years   (Adult, Older Adult)
  • Outcome measures - Mortality rate|Readmission rate
NCT04595136 Study to Evaluate the Efficacy of COVID19-0001-USR in Patients With Mild/or Moderate COVID-19 Infection in Outpatient Recruiting Phase 1|Phase 2 Nov/02/2020 Aug/30/2021
  • Alternative id - COVID19-0001-USR
  • Interventions - Drug: Drug COVID19-0001-USR|Drug: normal saline
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Cimedical, Barranquilla, Atlantico, Colombia
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 60
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Change on viral load results from baseline after using COVID19-0001-USR via nebulization
NCT05148780 A Study of Acute Respiratory Infections in Global Outpatient Setting Recruiting Early Phase 1 Dec/20/2021 Dec/31/2025
  • Alternative id - CR109104|NOPRODRSV4002
  • Interventions - Diagnostic Test: Nasal Swab Sample
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Lakeview Clinical Research, Guntersville, Alabama, United States|Synexus Clinical Research US, Inc, Mesa, Arizona, United States|Harrisburg Family Medical Center, Harrisburg, Arkansas, United States|Ark Clinical Research, Long Beach, California, United States|VA Sacramento Medical Center, Mather, California, United States|Yale New Haven Hospital, New Haven, Connecticut, United States|Innovative Research of West Florida, Incorporated, Clearwater, Florida, United States|Alma Clinical Research, Miami, Florida, United States|Columbus Regional Research Institute, Columbus, Georgia, United States|IACT Health, Rincon, Georgia, United States|Snake River Research, PLLC, Idaho Falls, Idaho, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Healor Primary Care, Las Vegas, Nevada, United States|Las Vegas Medical Research, Las Vegas, Nevada, United States|Santa Rosa Medical Centers of Nevada, Las Vegas, Nevada, United States|Montefiore Medical Center, Bronx, New York, United States|SUNY Downstate Medical Center, Brooklyn, New York, United States|Kernodle Clinic, Burlington, North Carolina, United States|American Health Network, LLC, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|DayStar Clinical Research, Inc., Akron, Ohio, United States|Lynn Institute of Norman, Norman, Oklahoma, United States|Ascension Medical Group - St. John Clinic Infectious Disease, Tulsa, Oklahoma, United States|Nashville VA Medical Center, Nashville, Tennessee, United States|Premier Family Physicians, Carrollton, Texas, United States|Southwest Family Medicine Associates, Dallas, Texas, United States|Accurate Clinical Management, LLC, Houston, Texas, United States|FMC Science, Lampasas, Texas, United States|Benchmark Research, San Angelo, Texas, United States|Intermountain Clinical Research, Draper, Utah, United States|IACT Health, Suffolk, Virginia, United States|MultiCare Health System, Tacoma, Washington, United States|Hospital Aleman, Buenos Aires, Argentina|Sanatorio de la Trinidad Mitre, Ciudad Autonoma Buenos Aires, Argentina|Hospital General de Agudos Donacion Francisco Santojanni, Ciudad Autonoma de Buenos Aires, Argentina|Hospital J. M. Ramos Mejía, Ciudad de Buenos Aires, Argentina|Sanatorio Allende, Cordoba, Argentina|Sanatorio Duarte Quiroz, Cordoba, Argentina|Instituto Médico DAMIC, Cordoba, Argentina|Hospital Español, La Plata, Argentina|Instituto Medico Platense, La Plata, Argentina|Clinica del Niño y la familia, Mar Del Plata, Argentina|Instituto Medico de La Fundacion Estudios Clinicos, Rosario, Argentina|Sanatorio Britanico S.A., Rosario, Argentina|Hospital Municipal de Vicente Lopez Dr. Bernardo Houssay, San Isidro, Argentina|Investigaciones en Patologias Respiratorias, San Miguel de Tucumán, Argentina|Instituto Del Buen Aire, Santa Fe, Argentina|Blacktown Hospital, Blacktown, Australia|Monash Medical Centre, Clayton, Australia|Westmead Hospital, Westmead, Australia|Hospital Brasília, Brasília, Brazil|Fundação Universidade Federal de Mato Grosso do Sul, Campo Grande, Brazil|Hrpc Ulbratech - Ulbra, Canoas, Brazil|CMiP - Centro Mineiro de Pesquisa, Juiz de Fora, Brazil|Complexo Hospitalar de Niterói, Niteroi, Brazil|Instituto Mederi de Pesquisa e Saude, Passo Fundo, Brazil|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil|Instituto de infectologia Emilio Ribas, Sao Paulo, Brazil|CMPC - Consultoria Médica e Pesquisa Clínica, Sorocaba, Brazil|Hospital Nove de Julho, São Paulo, Brazil|ALTA Clinical Research Inc., Edmonton, Canada|Xiangya Hospital, Central South University, Changsha, China|Changzhou No.2 People's Hospital, Changzhou, China|The Second Affiliated Hospital of Zhejiang University College of Medicine, Hangzhou, China|Qianfoshan hospital of Shandong Province, Jinan, China|Shanghai Zhongshan Hospital, Shanghai, China|ShangHai Huadong Hospital, Shanghai, China|Shanghai East Hospital, Shanghai, China|The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China|Medplus Medicina Prepagada S.A., Bogota, Colombia|IPS Caja de Compensacion Familiar CAFAM, Bogota, Colombia|Clínica Universitaria de la Sabana, Chia, Colombia|Fundacion Oftalmologica de Santander - FOSCAL, Floridablanca, Colombia|Funcentra, Monteria, Cordoba, Colombia|CHU Grenoble, La Tronche, France|Hopital Edouard Herriot - CHU Lyon, Lyon, France|Maison Medicale Rive Sud, Murs Erigne, France|CHU Nantes - Hotel Dieu, Nantes Cedex 1, France|CHU Tours - Hopital Bretonneau - Maladies Infectieuses, Tours, France|Berliner Centrum f. Reise- und Tropenmedizin (BCRT), Berlin, Germany|Zentrum für Infektiologie Berlin Prenzlauer Berg GmbH, Berlin, Germany|Praxis Dr. Keller, Frankfurt, Germany|medicoKIT GmbH, Goch, Germany|Clinical Research HamburggmbH, Hamburg, Germany|Universitaetsklinikum Koeln, Köln, Germany|Universitaetsklinikum Schleswig-Holstein - Campus Luebeck, Luebeck, Germany|Universitaetsmedizin Rostock, Rostock, Germany|Gemeinschaftspraxis, Wallerfing, Germany|Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII), Bergamo, Italy|Ospedale Policlinico San Martino IRCCS, Genova, Italy|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy|Ospedale San Raffaele, Milano, Italy|Fondazione IRCCS Policlinico San Matteo, Pavia, Italy|Azienda Sanitaria Locale N. 2 Savonese - Presidio ospedaliero di Albenga - Ospedale Santa Corona, Pietra Ligure, Italy|Istituto Clinico Humanitas, Rozzano, Italy|Fujita Health University Hospital, Date-gun, Japan|Fukuoka University Hospital, Fukuoka, Japan|Hiroshima Prefectural Hospital, Hiroshima-shi, Japan|Kurashiki Central Hospital, Kurashiki, Japan|Shinrakuen Hospital, Niigata, Japan|Miyagikoseikyokai Saka General Hospital, Shiogama, Japan|Korea University Ansan Hospital, Ansan-si, Korea, Republic of|Inje University Busan Paik Hospital, Busan, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Korea University Guro Hospital, Seoul, Korea, Republic of|Hallym University Kangnam Sacred Heart Hospital, Seoul, Korea, Republic of|Klinik Kesihatan Putrajaya Presint 9, Kuala Lumpur, Malaysia|Hospital Sultanah Nur Zahirah, Kuala, Malaysia|Klinik Kesihatan Kuang, Kuang, Malaysia|Klinik Kesihatan Masjid Tanah, Masjid Tanah, Malaysia|Hospital Miri, Miri, Malaysia|CIAME, Cancun, Mexico|Hospital CIMA Chihuahua, Chihuahua, Mexico|Centro de Investigación Clínica Gramel S.C., Ciudad de Mexico, Mexico|CEMDEC SA de CV, Ciudad de México, Mexico|Centro de Investigacion Medico Biologica y Terapia Avanzada CIMBYTA, Guadalajara, Mexico|Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico|Instituto Nacional de Enfermedades Respiratorias, Mexico, Mexico|Centro de Investigacion y Transferencia en Salud, Fundacion Santos y de la Garza Evia, IBP, Monterrey, Mexico|Oaxaca Site Management Organization S.C., Oaxaca, Mexico|Unidad de Proyectos Clínicos de Oriente UPCO, Valladolid, Mexico|Hospital General de Occidente, Zapopan, Mexico|NEURO-MEDIC Janusz Zbrojkiewicz Poradnia Wielospecjalistyczna, Katowice, Poland|Centrum Innowacyjnych Terapii Sp. z o.o., Piaseczno, Poland|EMC Instytut Medyczny SA PL CERTUS, Poznan, Poland|Gabinet Pulmonologii i Diagnostyki Chorob Alergicznych, Szczecin, Poland|NZOZ Leczniczo-Rehabilitacyjny Ośrodek Medycyny Rodzinnej, Wrocław, Poland|Eap Sardenya, Barcelona, Spain|Cap Apenins - Montigala, Caldes Montbui Canovelles, Spain|Cap Canet de Mar, Canet de Mar, Spain|Cap Centelles, Centelles, Spain|Hosp. Clinico San Carlos, Madrid, Spain|Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|Taipei Medical University Shuang Ho Hospital, New Taipei, Taiwan|Taipei Medical University, Taipei City, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|Tri-Service General Hospital, Taipei, Taiwan|Taipei Municipal Wanfang Hospital, Taipei, Taiwan|Siriraj Hospital, Bangkok, Thailand|Srinagarind Hospital, Khon Kaen, Thailand|Ormeau Clinical Trials Ltd, Belfast, United Kingdom|West Walk Surgery, Bristol, United Kingdom|Hathaway Medical Centre, Chippenham, United Kingdom|Royal Devon and Exeter Hospital(Wonford), Exeter, United Kingdom|Mounts Bay Medical Ltd, Hayle, United Kingdom|Leicester Royal Infirmary, Leicester, United Kingdom|St George's Hospital, London, United Kingdom|Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom|Southampton General Hospital, Poole, United Kingdom|Tieve Tara Medical Centre, Wakefield, United Kingdom|Sheepcot Medical Centre, Watford, United Kingdom|The Adam Practice, Wirral, United Kingdom
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other
  • Enrollment - 2960
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Percentage of Participants Positive for Respiratory Syncytial Virus (RSV)|Percentage of Participants Positive for Influenza Virus|Percentage of Participants Positive for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)|Number of Participants with Relative Risk of Acute Respiratory Infections (ARI)- related Hospitalization in Participants Positive for RSV with Lower Respiratory Tract Disease (LRTD) or Without LRTD|Number of Participants with Relative Risk of ARI-related Hospitalization in Participants Positive for Influenza Virus Diagnosed with or Without LRTD|Number of Participants with Relative Risk of ARI-related Hospitalization in Participants Positive for SARS-CoV-2 with or Without LRTD|Percentage of Participants Positive for RSV Reporting ARI-related Hospitalizations During the Study Period|Percentage of Participants Positive for Influenza Virus Reporting ARI-related Hospitalizations During the Study Period|Percentage of Participants Positive for SARS-CoV-2 Reporting ARI-related Hospitalizations During the Study Period|Time to ARI- related Hospitalization in Participants Positive for RSV|Time to ARI- related Hospitalization in Participants Positive for Influenza Virus|Time to ARI- related Hospitalization in Participants Positive for SARS-CoV-2|Percentage of Participants Presenting with Complications at Screening and Diagnosed with or Without LRTD|Percentage of Participants Reporting ARI- related Complications During the Follow-up Period and Diagnosed with or Without LRTD|Time to ARI- related Complications During the Follow-up Period in Participants Positive for RSV|Time to ARI- related Complications During the Follow-up Period in Participants Positive for Influenza Virus|Time to ARI- related Complications During the Follow-up Period in Participants Positive for SARS-CoV-2|Percentage of Participants Presenting with Clinically Relevant Disease at Screening and Diagnosed with or Without LRTD|Percentage of Participants Reporting ARI- related Clinically Relevant Disease During the Follow-up Period and Diagnosed with or Without LRTD|Time to ARI-related Clinically Relevant Disease During the Follow-up Period in Participants Positive for RSV|Time to ARI-related Clinically Relevant Disease During the Follow-up Period in Participants Positive for Influenza Virus|Time to ARI-related Clinically Relevant Disease During the Follow-up Period in Participants Positive for SARS-CoV-2
NCT04407663 Outpatient Clinic in Obesity Care During COVID-19 Outbreak: Physically Far, Virtually Near Completed Mar/03/2020 May/04/2020
  • Alternative id - Telemedicine
  • Interventions - Other: Telemedicine to remote outpatient visit in bariatric patient
  • Study type - Observational
  • Study results - No Results Available
  • Locations - University of Campania "Luigi Vanvitelli", Naples, Italy
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 138
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Evaluation of feasibility of telemedicine in outpatient visit in bariatric patients
NCT05096819 Evaluation of the Usefulness of Adopting Remote, Mobile-based 6MWT Among Hospital Outpatients (the 6-APPnow), Within the Constraints Imposed by the SARS-COV2 Pandemic Recruiting Sep/01/2021 Dec/01/2023
  • Alternative id - PID15408
  • Interventions - Other: App
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
  • Study designs - Observational Model: Case-Only|Time Perspective: Prospective
  • Enrollment - 500
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of patients undertaking a 6MWT.|To measure the accuracy of the app-based measurement.|To measure differences in distance walked according to the app altered management of patients.|Did the patients use the app|To determine whether the use of the 6MWT reduces time spent and number in hospital visits.|Number of patients undertaking a 6MWT during the pandemic period
NCT04583592 Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT) Completed Phase 2 Nov/09/2020 Mar/31/2021
  • Alternative id - NI03-CV19-001
  • Interventions - Drug: Camostat Mesilate|Drug: Placebo
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Palmtree Clinical Research, Inc. (Site 125), Palm Springs, California, United States|Synergy Healthcare, LLC (Site 124), Bradenton, Florida, United States|Clinical Research of Brandon, LLC (Site 123), Brandon, Florida, United States|Reliable Clinical Research, LLC (Site 100), Hialeah, Florida, United States|A+ Research (Site 112), Miami, Florida, United States|NextPhase Research Alliance at CANO HEALTH (Site 107), Miami, Florida, United States|Ezy Medical Research (Site 106), Miami, Florida, United States|Eminat LLC (Site 117), Plantation, Florida, United States|Invictus Clinical Research Group, LLC (Site 101), Pompano Beach, Florida, United States|Visionaries Clinical Research, LLC (Site 121), Atlanta, Georgia, United States|Family Care Research (Site 114), Boise, Idaho, United States|Cedar Crosse Research Center (Site 122), Chicago, Illinois, United States|Massachusetts General Hospital (Site 110), Boston, Massachusetts, United States|Oakland Medical Research Center (Site 108), Troy, Michigan, United States|Cary Research Group (Site 111), Cary, North Carolina, United States|Onsite Solutions (Site 118), Charlotte, North Carolina, United States|STAT Research (Site 109), Springboro, Ohio, United States|Toledo Institute of Clinical Research, Inc.(Site 105), Toledo, Ohio, United States|Advanced Medical Trials (Site 104), Georgetown, Texas, United States|Next Innovative Clinical Research (Site 115), Houston, Texas, United States|Rio Grand Valley Clinical Research Institute (Site 120), Pharr, Texas, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 295
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Disease Progression at Day 28|Survival Rate|Time to Fever Resolution|Resolution of Viral Shedding|Rate of Adverse Events and Serious Adverse Events|Cumulative Rate of Grade 3 and 4 Adverse Events|Rate of Discontinuation|Laboratory Parameter - Platelet Count|Laboratory Parameter - Potassium Level|Laboratory Parameter - Aspartate Aminotransferase (AST)|Laboratory Parameter - Alanine Aminotransferase (ALT)|Laboratory Parameter - Alkaline Phosphatase (ALP)|Laboratory Parameter - Gamma-Glutamyl Transferase (GGT)|Vital Signs - Heart Rate|Vital Signs - Blood Pressure|Vital Signs - Peripheral Capillary Oxygen Saturation (SpO2)
NCT04584697 Study to Evaluate the Safety, Pharmacokinetics and Efficacy of STI-2020 (COVI-AMG™) in Outpatients With COVID-19 Withdrawn Phase 1|Phase 2 Dec/01/2020 Apr/01/2021
  • Alternative id - AMG-COV-102
  • Interventions - Biological: COVI-AMG|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Incidence of adverse events by type, frequency, severity, and causality (safety)|Incidence of treatment-emergent adverse events by type, frequency, severity, and causality (safety)|Incidence of serious adverse events by type, frequency, severity, and causality (safety)|Incidence of dose-limiting toxicities (safety)|Incidence of clinically meaningful laboratory abnormalities (safety)|Viral load as assessed using plasma and salivary samples at various timepoints|Time from onset of COVID-19 symptoms to treatment (Day 1)|Presence and levels of anti-drug antibodies directed to COVI-AMG|Cytokine levels post-treatment|AUC of COVI-AMG (PK)|Cmax of COVI-AMG (PK)|Tmax of COVI-AMG (PK)|t½ of COVI-AMG (PK)
NCT04723394 Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults Active, not recruiting Phase 3 Jan/28/2021 Oct/21/2022
  • Alternative id - D8851C00001
  • Interventions - Drug: AZD7442|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Research Site, Jasper, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Long Beach, California, United States|Research Site, Northridge, California, United States|Research Site, Cutler Bay, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Pompano Beach, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Lake Charles, Louisiana, United States|Research Site, Saint Louis, Missouri, United States|Research Site, La Vista, Nebraska, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Statesville, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Columbus, Ohio, United States|Research Site, West Columbia, South Carolina, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Humble, Texas, United States|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Munro, Argentina|Research Site, Blumenau, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Sorocaba, Brazil|Research Site, São Paulo, Brazil|Research Site, Bilina, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Kolin, Czechia|Research Site, Ostrava, Czechia|Research Site, Berlin - Friedrichshain, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Frankfurt/Main, Germany|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Koblenz, Germany|Research Site, Köln, Germany|Research Site, Mainz, Germany|Research Site, München-Pasing, Germany|Research Site, München, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyöngyös, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Tatabánya, Hungary|Research Site, Bologna, Italy|Research Site, Guastalla, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Piacenza, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Chiba-shi, Japan|Research Site, Hachioji-shi, Japan|Research Site, Iruma-Gun, Japan|Research Site, Kyoto-shi, Japan|Research Site, Maebashi-shi, Japan|Research Site, Narita-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Chihuahua, Mexico|Research Site, Cuauhtemoc, Mexico|Research Site, Cuautitlan Izcalli, Mexico|Research Site, Ecatepec de Morelos, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mazatlán, Mexico|Research Site, Monterrey, Mexico|Research Site, Mérida, Mexico|Research Site, Tlalpan, Mexico|Research Site, Tlalpan, Mexico|Research Site, Lima, Peru|Research Site, Rzeszów, Poland|Research Site, Wołomin, Poland|Research Site, Moscow, Russian Federation|Research Site, Murmansk, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Cabra, Spain|Research Site, Centelles (Barcelona), Spain|Research Site, Girona, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Dnipro, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kherson, Ukraine|Research Site, Blackpool, United Kingdom|Research Site, Bracknell, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Connor Downs, United Kingdom|Research Site, Highgate, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Preston, United Kingdom|Research Site, Rochdale, United Kingdom
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 910
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - A composite of either severe COVID-19 or death from any cause through Day 29.|AEs, SAEs, and AESIs through end of study.|A composite of either death from any cause or hospitalization for COVID-19 complications or sequelae during the 168-day post-dose period (Day 1 to Day 169).|The incidence of participants with respiratory failure, defined as requirement for mechanical ventilation, ECMO, non-invasive ventilation, or high-flow nasal cannula oxygen delivery.|COVID-19 symptom severity assessments based on symptom severity scores over time during the 28-day period from and including the day of the dose of AZD7442 or placebo.|Progression through Day 29 of one or more COVID-19-associated symptoms to a worse status than recorded in the participant-reported symptom diary at study entry, prior to start of AZD7442 or placebo.|Detection (detectable versus undetectable) from baseline of SARS-CoV-2 RNA from nasal swabs through Day 29.|Level of SARS-CoV-2 RNA from nasal swabs through Day 29.|Change from baseline of SARS-CoV-2 RNA from nasal swabs through Day 29.|Time to return to usual (pre-COVID-19) health through Day 29.|Duration of fever through Day 29 defined as the last day in the participant-reported symptom diary on which a temperature greater than 100°F (37.8° C) was recorded or a potentially antipyretic drug, such as acetaminophen or ibuprofen, was taken.|Incidence of ADA to AZD7442 in serum over time.|Pharmacokinetics - Serum Concentration|Pharmacokinetics - Maximum Serum Concentration|Pharmacokinetics - Time to Maximum Serum Concentration|Pharmacokinetics - Area under the plasma concentration-time curve to the last measurable time point|Pharmacokinetics - Area under the plasma concentration-time curve extrapolated to infinity
NCT04870606 Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness Recruiting Phase 3 Mar/05/2021 May/24/2022
  • Alternative id - GT0918-US-3001
  • Interventions - Drug: Proxalutamide (GT0918)|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Absolute Clinical Research, Phoenix, Arizona, United States|Long Beach Clinical Trials, Long Beach, California, United States|WR-Mount Vernon Clinical Research, LLC, Sandy Springs, Georgia, United States|Olivo Medical and Wellness Center, Chicago, Illinois, United States|Gtc Research, Shawnee Mission, Kansas, United States|Platinum Research Network, LLC, Metairie, Louisiana, United States|Main Street Physician's Care, Little River, South Carolina, United States|Lotus Clinical Research, Houston, Texas, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 668
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Efficacy of Proxalutamide
NCT04474483 Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19 Recruiting Phase 2 Nov/06/2020 Dec/31/2022
  • Alternative id - UBMELCOVID19
  • Interventions - Drug: Melatonin|Other: Placebo (Methylcellulose) capsule
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University at Buffalo, Buffalo, New York, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 30
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Cumulative Incidence of Treatment-Emergent Adverse Events|Hospitalization|COVID-19 related symptoms|Rate of resolution of COVID-19 related symptoms|Mortality
NCT04338841 HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection Completed Not Applicable Apr/09/2020 Jun/17/2020
  • Alternative id - 2020-A00831-38
  • Interventions - Other: HOME-CoV rule implementation
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Clinique Universitaire Saint-Luc, Bruxelles, Belgium|CHU de Liège, Liege, Belgium|Ch Argenteuil, Argenteuil, France|CH Cholet, Cholet, France|CHU Clermont Ferrand, Clermont Ferrand, France|Ch Colmar, Colmar, France|CH Alpes Lemant, Contamine-sur-Arve, France|CHU Dijon, Dijon, France|CH Le Mans, Le Mans, France|CH Libourne, Libourne, France|CH Limoges, Limoges, France|Ch Longjumeau, Longjumeau, France|Chu Montpellier, Montpellier, France|Centre Hospitalier Universitaire de Nantes, Nantes, France|CH Niort, Niort, France|Hopital Paris Saint Joseph, Paris, France|Hopital Saint Antoine, Paris, France|Hôpital Bichat, Paris, France|Hôpital Lariboisière, Paris, France|CHU de Poitiers, Poitiers, France|CH Reims, Reims, France|Ch Remiremont, Remiremont, France|Chu Rennes, Rennes, France|CHU de Rouen, Rouen, France|CHU de St Etienne, Saint Etienne, France|CH de Saint-Brieuc, Saint-Brieuc, France|Ch Troyes, Troyes, France|CH VICHY, Vichy, France|CH Princesse Grace, Monaco, Monaco
  • Study designs - Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 3133
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - the composite rate of adverse outcomes|The rate of hospitalization
NCT04614701 Correlation of Carotid Flow Time and Cardiac Output. Not yet recruiting Sep/01/2022 Mar/31/2023
  • Alternative id - HS24296
  • Interventions - Procedure: Carotid Artery Ultrasound Measure
  • Study type - Observational
  • Study results - No Results Available
  • Locations - St. Boniface General Hospital, Winnipeg, Manitoba, Canada
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 20
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Change in measured LVOT VTI by bedside echocardiography|Changed in corrected carotid artery flow time as measured by bedside carotid artery ultrasonography.
NCT04334382 Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 Recruiting Phase 3 Apr/02/2020 Dec/31/2021
  • Alternative id - 1051360
  • Interventions - Drug: Hydroxychloroquine|Drug: Azithromycin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 1550
  • Age - 45 Years and older   (Adult, Older Adult)
  • Outcome measures - Hospitalization within 14 days of enrollment|Duration of COVID-19-attributable symptoms|Hospital-free days at 28 days|Ventilator-free days at 28 days|ICU-free days at 28 days
NCT04900428 Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK) Active, not recruiting Phase 2 Jul/18/2021 Jul/01/2022
  • Alternative id - DRP-COV-201UK
  • Interventions - Biological: COVI-DROPS|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University Hospitals of Coventry and Warwickshire Hospital Trust, Coventry, United Kingdom
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 350
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Viral load change from baseline to D8|The number of COVID-19-related urgent medically attended visits, emergency department assessments or hospitalizations through D29|Proportion of subjects alive and free of hospitalization ˃ 24h duration for acute COVID-19 illness management through D29|Change in WHO Clinical Progression Scale score|Worst WHO Clinical Progression Scale score up to D8 and from D9 to D29|Viral load change from baseline to D29 based on RT-PCR determined COVID-19 viral titers (Log-10 copies/mL) from nasopharyngeal swabs|Change in patient-reported COVID-19 symptoms
NCT05074394 Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 Infection Withdrawn Phase 2 Nov/01/2021 Jan/01/2023
  • Alternative id - DRP-COV-206US
  • Interventions - Biological: COVI-DROPS|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Proportion of subjects who have a COVID-19-related visit or hospitalization|Viral load change from baseline to Day 15 (D15)|Proportion of subjects who have a COVID-19-related visit or hospitalization based on stratification groups
NCT04666441 COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection Completed Phase 2 Dec/15/2020 Sep/21/2021
  • Alternative id - R10933-10987-COV-20145
  • Interventions - Drug: REGN10933+REGN10987 combination therapy|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Regeneron Study Site, Mesa, Arizona, United States|Regeneron Study Site, Tucson, Arizona, United States|Regeneron Study Site, Canoga Park, California, United States|Regeneron Study Site, Long Beach, California, United States|Regeneron Study Site, Los Angeles, California, United States|Regeneron Study Site, Rolling Hills Estates, California, United States|Regeneron Study Site, San Francisco, California, United States|Regeneron Study Site, Santa Monica, California, United States|Regeneron Study Site, Stanford, California, United States|Regeneron Study Site, Colorado Springs, Colorado, United States|Regeneron Study Site, Washington, District of Columbia, United States|Regeneron Study Site, DeLand, Florida, United States|Regeneron Study Site, Fort Pierce, Florida, United States|Regeneron Study Site, Hialeah, Florida, United States|Regeneron Study Site, Hialeah, Florida, United States|Regeneron Study Site, Maitland, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Miami, Florida, United States|Regeneron Study Site, Saint Petersburg, Florida, United States|Regeneron Study Site, Tampa, Florida, United States|Regeneron Study Site, West Palm Beach, Florida, United States|Regeneron Study Site, Winter Haven, Florida, United States|Regeneron Study Site, Winter Park, Florida, United States|Regeneron Study Site, Atlanta, Georgia, United States|Regeneron Study Site, Columbus, Georgia, United States|Regeneron Study Site, Downers Grove, Illinois, United States|Regeneron Study Site, Ames, Iowa, United States|Regeneron Study Site, Iowa City, Iowa, United States|Regeneron Study Site, Lake Charles, Louisiana, United States|Regeneron Study Site, Marrero, Louisiana, United States|Regeneron Study Site, Shreveport, Louisiana, United States|Regeneron Study Site, Baltimore, Maryland, United States|Regeneron Study Site, Las Vegas, Nevada, United States|Regeneron Study Site, Teaneck, New Jersey, United States|Regeneron Study Site, Bronx, New York, United States|Regeneron Study Site, New York, New York, United States|Regeneron Study Site, Charlotte, North Carolina, United States|Regeneron Study Site, Durham, North Carolina, United States|Regeneron Study Site, Wilmington, North Carolina, United States|Regeneron Study Site, Columbus, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Dayton, Ohio, United States|Regeneron Study Site, Philadelphia, Pennsylvania, United States|Regeneron Study Site, Charleston, South Carolina, United States|Regeneron Study Site, Clinton, South Carolina, United States|Regeneron Study Site, Amarillo, Texas, United States|Regeneron Study Site, Corpus Christi, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Houston, Texas, United States|Regeneron Study Site, Pearland, Texas, United States|Regeneron Study Site, Red Oak, Texas, United States|Regeneron Study Site, San Antonio, Texas, United States|Regeneron Study Site, Splendora, Texas, United States|Regeneron Study Site, Tyler, Texas, United States|Regeneron Study Site, Falls Church, Virginia, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 1164
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Time-weighted average daily change from baseline in viral load (log10 copies/mL), as measured by reverse transcription quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal (NP) swab samples|Time-weighted average daily change from baseline in viral load (log10 copies/mL)|Time-weighted average daily change from baseline in viral load (log10 copies/mL) in patients with high viral load at baseline|Proportion of patients with high viral load|Proportion of patients with viral loads below the limit of detection|Proportion of patients with viral loads below the lower limit of quantification|Change from baseline in viral load (log10 copies/mL) as measured by RT-qPCR in NP samples|Proportion of patients with treatment-emergent serious adverse events (SAEs)|Proportion of patients with infusion-related reactions (grade ≥2)|Proportion of patients with injection-site reactions (grade ≥3)|Proportion of patients with hypersensitivity reactions (grade ≥2)|Concentrations of REGN10933 in serum|Concentrations of REGN10987 in serum|Immunogenicity as measured by anti-drug antibodies (ADAs) to REGN10933|Immunogenicity as measured by neutralizing anti-drug antibody (NAb) to REGN10933|Immunogenicity as measured by anti-drug antibodies (ADAs) to REGN10987|Immunogenicity as measured by neutralizing anti-drug antibody (NAb) to REGN10987
NCT04498273 COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80 Terminated Phase 3 Sep/07/2020 Aug/05/2021
  • Alternative id - ACTIV4-Outpatient
  • Interventions - Drug: Apixaban 2.5 MG|Drug: Apixaban 5MG|Drug: Aspirin|Drug: Placebo
  • Study type - Interventional
  • Study results - Has Results
  • Locations - University of Southern California, Los Angeles, California, United States|Stanford University School of Medicine, Palo Alto, California, United States|Zuckerberg San Francisco General, San Francisco, California, United States|Olive View-UCLA Medical Center, Sylmar, California, United States|Pine Ridge Family Medicine, Colorado Springs, Colorado, United States|Life Tree Health, Inc., Washington, District of Columbia, United States|Midland Florida Clinical Research Center, LLC, DeLand, Florida, United States|University of Florida at Gainesville, Gainesville, Florida, United States|Vital Pharma Research, Hialeah, Florida, United States|Advanced Research for Health Improvement, LLC, Immokalee, Florida, United States|University of Floridia at Jacksonville, Jacksonville, Florida, United States|Lakeland Regional, Lakeland, Florida, United States|Total Research Group LLC, Miami, Florida, United States|Jackson Memorial, Miami, Florida, United States|Well Pharma Medical Research, Miami, Florida, United States|Innovation Clinical Trials, Palmetto Bay, Florida, United States|Bond Community Health Center, Tallahassee, Florida, United States|Tallahassee Memorial, Tallahassee, Florida, United States|USF Tampa General Hospital, Tampa, Florida, United States|Alliance Clinical Research, Tampa, Florida, United States|Hawaii Pacific Health, Honolulu, Hawaii, United States|Fox Valley Clinical Research Center, LLC, Aurora, Illinois, United States|UIC - Mile Square, Chicago, Illinois, United States|Jesse Brown VA, Chicago, Illinois, United States|University of Illinois at Chicago, Chicago, Illinois, United States|Olivo Wellness Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|OSF Saint Francis Medical Center, Peoria, Illinois, United States|Ascension Via Christi, Wichita, Kansas, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Jadestone Clinical Research, LLC, Gaithersburg, Maryland, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|GFC of Southeastern Michigan, Detroit, Michigan, United States|SRI International, Plymouth, Michigan, United States|Metro Health-University of Michigan Health, Wyoming, Michigan, United States|Raritan Bay Primary Care and Cardiology Associates, Matawan, New Jersey, United States|G&S Medical Associates, LLC, Paterson, New Jersey, United States|University of New Mexico, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|Strong Memorial, Rochester, New York, United States|Spinal Pain and Rehab Medicine, Yonkers, New York, United States|Duke, Durham, North Carolina, United States|Peters Medical Research, High Point, North Carolina, United States|The Heart and Medical Center, Durant, Oklahoma, United States|Ascension St. John Clinical Research Institute, Tulsa, Oklahoma, United States|UPMC Passavant Cranberry, Cranberry, Pennsylvania, United States|UPMC McKeesport, McKeesport, Pennsylvania, United States|UPMC East, Monroeville, Pennsylvania, United States|UPMC Magee, Pittsburgh, Pennsylvania, United States|UPMC Presby, Pittsburgh, Pennsylvania, United States|UPMC Mercy, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States|UPMC Shadyside, Pittsburgh, Pennsylvania, United States|UPMC Passavant McCandless, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Inc, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Pittsburgh, Pennsylvania, United States|Preferred Primary Care Physicians, Uniontown, Pennsylvania, United States|Pharma Tex Research, Amarillo, Texas, United States|Ascension Seton Medical Center, Austin, Texas, United States|Baptist Beaumont, Beaumont, Texas, United States|McGoven Medical School - UT- Houston, Houston, Texas, United States|Diversifield Medical Practices, Houston, Texas, United States|Next Level Urgent Care, Houston, Texas, United States|Mesquite Regional Internal Medicine, Mesquite, Texas, United States|University of Texas at Tyler, Tyler, Texas, United States|University of Texas at Rio Grande Valley, Weslaco, Texas, United States|Intermountain Healthcare, Murray, Utah, United States|Community Care of Clay, Clay, West Virginia, United States|University Healthcare Physicians, Harpers Ferry, West Virginia, United States|Community Care of Weston, Weston, West Virginia, United States|Gundersen Health System, La Crosse, Wisconsin, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention
  • Enrollment - 657
  • Age - 40 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Hospitalization for Cardiovascular/Pulmonary Events
NCT04662086 COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol Recruiting Phase 2 Apr/23/2021 Aug/01/2022
  • Alternative id - COPPS-Master Protocol
  • Interventions - Drug: Acebilustat|Drug: Camostat
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - ValleyCare Medical Center, Pleasanton, California, United States|Stanford University, Stanford, California, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 240
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - For Viral Domain: Change in Viral Shedding|For Clinical Domain: Time-to-sustained-resolution|Time to viral cessation|Time to first resolution|Time to full resolution|Indicator of SARS-CoV-2 related hospitalizations, ED visits, or death in outpatients with COVID-19 disease.|Indicator participant has developed antibodies to SARS-CoV-2
NCT04907877 Bifido- and Lactobacilli in Symptomatic Adult COVID-19 Outpatients Recruiting Not Applicable Dec/01/2021 Sep/01/2022
  • Alternative id - MS-Resp-CoV-2-A0003
  • Interventions - Dietary Supplement: Probiotic|Dietary Supplement: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hemo Medica Ukraine Ltd, Uzhhorod, Zakarpatska, Ukraine|Lviv State Center for Disease Control and Prevention, Lviv, Ukraine|3rd City Clinical Hospital of Lviv, Lviv, Ukraine
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 300
  • Age - 18 Years to 65 Years   (Adult, Older Adult)
  • Outcome measures - Global symptom score|8 - point ordinal severity scale of coronavirus disease-19|Time to recovery|Percent of completely recovered patients|Hospitalization rate|Proportion of symptomatic infection
NCT04784754 Dose-Ranging Study to Assess the Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19 Recruiting Phase 2 Apr/01/2021 Dec/31/2022
  • Alternative id - UBMELCOVID19-P|UL1TR001412
  • Interventions - Drug: Melatonin|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University at Buffalo, Buffalo, New York, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 50
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Cumulative Incidence of Treatment-Emergent Adverse Events|Incidence of COVID-19 related hospitalization|COVID-19 related symptoms|Rate of resolution of COVID-19 related symptoms|Mortality
NCT04619290 Outpatient Treatment With CoVid-19 With Prexablu Recruiting Phase 1 Oct/12/2020 Dec/30/2020
  • Alternative id - 064.I.2020
  • Interventions - Drug: Sublingual Methylene blue|Other: Control patients
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Hospital Regional Lic Adolfo Lopez Mateos, Mexico City, Ciudad De Mexico CDMX (Mexico City), Mexico
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 46
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Change form baseline in Arterial oxygen saturation|Days to clinical improvement|Change Form Baseline in C reactive protein at 7 days|Change Form Baseline in IL-1β|Change Form Baseline in Erythrocyte sedimentation rate like procalcitonin|Change Form Baseline in Ferritin levels|Change Form Baseline in D dimer
NCT04370782 Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting Completed Phase 4 Apr/28/2020 Sep/30/2020
  • Alternative id - 20-21
  • Interventions - Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Zinc Sulfate|Drug: Doxycycline
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - St Francis Hospital, Roslyn, New York, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 18
  • Age - 30 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to Resolution of Symptoms relative to baseline (day 1 of trial)|Number of participants hospitalized and/or requiring repeat ER visits|ICU Length of Stay|Ventilator|Severity of symptoms|Number of participants with adverse events due to drug regimen|Number of participants with QTc prolongation >500ms
NCT04743609 RSV Burden in Outpatient Settings Recruiting Feb/08/2021 Jan/11/2023
  • Alternative id - 2020-A02876-33
  • Interventions - Diagnostic Test: nasopharyngeal samples
  • Study type - Observational
  • Study results - No Results Available
  • Locations - ACTIV, Créteil, France
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 2900
  • Age - up to 24 Months   (Child)
  • Outcome measures - RSV proven|Proportion of Respiratory Tract Infections by RSV Status|Proportion of Respiratory Tract Infections with SARS-CoV-2|Proportion of associated complications by RSV status|Proportion of AOM by RSV status|Proportion of pneumonia by RSV status|Score of Quality of life|Caracteristic of tests
NCT04729140 An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization Recruiting Phase 4 Dec/28/2020 Mar/28/2022
  • Alternative id - COVIVER-OUT PLUS
  • Interventions - Drug: Ivermectin Tablets|Drug: Doxycycline Tablets|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - MAX HEALTH, Subsero Health 2055 Wood Street, Suite 100, Sarasota, Florida, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 150
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Decreased admission rate to the hospital secondary to respiratory illness related to COVID-19|Decrease in total duration of symptoms secondary to respiratory illness related to COVID-19|Assessment of White Blood Cell Count|Assessment of Hemoglobin level|Assessment of Hematocrit level|Assessment of Platelet Count|Assessment of Sodium level|Assessment of Potassium level|Assessment of Chloride level|Assessment of Carbon Dioxide level|Assessment of Blood Urea Nitrogen level|Assessment of Creatinine level|Assessment of Calcium level|Assessment of Glucose level|Assessment of Total Bilirubin level|Assessment of Total Protein level|Assessment of Albumin level|Assessment of Aspartate Aminotransferase level|Assessment of Alanine Aminotransferase level|Assessment of Alkaline Phosphatase level|Assessment of Ferritin|Assessment of D-dimer|Assessment of Creatine Phosphokinase|Assessment of C-Reactive Protein|Assessment of Prothrombin Time and International Normalized Ratio|Assessment of activated Partial Thromboplastin Time|Assessment of Fibrinogen Activity|Assessment of Interleukin 6 level|Assessment of Interleukin 6 receptor level|Assessment of Tumor Necrosis Factor Alpha level|Assessment of Tumor Necrosis Factor Alpha Receptor level|Mortality|Measurement of Participants with Medication Side Effects|Measurement of Participants with new onset Shortness of Breath or Changes in Shortness of Breath Severity|Measurement of Participants Pulse Oximetry readings on room air|Measurement of Participants with new onset Red Eyes or Changes in Red Eyes Severity|Measurement of Participants with new onset Chills or Changes in Chills Severity|Measurement of Participants with new onset Runny Nose or Changes in Runny Nose Severity|Measurement of Participants with new onset Sore Throat or Changes in Sore Throat Severity|Measurement of Participants with new onset Loss of Smell or Changes in Severity of in Loss of Smell|Measurement of Participants with new onset Loss of Taste or Changes in Severity of Loss of Taste|Measurement of Participants with new onset Body Aches or Body Pains or Changes in Body Aches or Body Pains Severity|Measurement of Participants with new onset Diarrhea or Changes in Diarrhea Severity|Measurement of Participants with new onset Headaches or Changes in Headaches Severity|Measurement of Participants with new onset Anxiety or Changes in Anxiety Severity|Measurement of Participants with new onset Fatigue or Changes in Fatigue Severity|Measurement of Participants with new onset Trouble Concentrating or Changes in Trouble Concentrating Severity|Measurement of Participants with new onset Cough or Changes in Cough Severity|Measurement of Participants with new onset Vomiting or Changes in Vomiting Severity|Measurement of Participants with new onset Nausea or Changes in Nausea Severity|Measurement of Participants with new onset Feelings of Hopelessness or Changes in Feelings of Hopelessness severity|Measurement of Participants with new onset feelings of Depression or Changes in feelings of Depression severity|Measurement of Participants with new onset Fever or Changes in Fever Severity|Measurement of Participants with new onset Moving Slowly or Changes in the Severity of Moving Slowly|Measurement of Participants with new onset Speaking Slowly or Changes in the Severity of Speaking Slowly|Measurement of Participants with new onset Feelings of Restlessness or Changes in the Severity of Feelings of Restlessness|Measurement of Participants with new onset Thoughts of Better Off Being Dead or Changes in the Severity of Thoughts of Better Off Being Dead|Measurement of Participants with new onset Thoughts of Hurting Yourself or Changes in the Severity of Thoughts of Hurting Yourself|Measurement of Participants with new onset Loss of Interest in Doing Things or Changes in the Severity of Loss of Interest in Doing Things|Measurement of Participants with new onset Loss of Pleasure in Doing Things or Changes in the Severity of Loss of Pleasure in Doing Things|Measurement of Participants with new onset Trouble Falling Asleep or Changes in the Severity of Trouble Falling Asleep|Measurement of Participants with new onset Trouble Staying Asleep or Changes in the Severity of Trouble Staying Asleep|Measurement of Participants with new onset Unmentioned Negative Impacts of COVID 19 infection or Changes in the Severity of these Negative Impacts of COVID 19 infection
NCT04354428 Treatment for COVID-19 in High-Risk Adult Outpatients Active, not recruiting Phase 2|Phase 3 Apr/16/2020 Jan/01/2021
  • Alternative id - STUDY00009878|INV-017062
  • Interventions - Drug: Ascorbic Acid|Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Folic Acid|Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Ruth M. Rothstein CORE Center - Cook County Health, Chicago, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Boston University, Boston, Massachusetts, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 300
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Lower respiratory tract infection (LRTI) rates|Incidence of hospitalization or mortality|Change in upper respiratory viral shedding|COVID-19 symptom resolution rates [Lopinavir-ritonavir arm only]|Rate of participant-reported adverse events|COVID-19-related hospitalization days|Rate of disease severity|Viral shedding rates|Individual lopinavir-ritonavir concentration profiles and exposure estimates [Lopinavir-ritonavir arm only]
NCT05045937 Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19 Not yet recruiting Sep/20/2021 Sep/20/2023
  • Alternative id - Ivermectin Treatment Study #1
  • Interventions - Drug: Ivermectin
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Patrick Robinson MD LLC, San Antonio, Florida, United States
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 1000
  • Age - 12 Years to 110 Years   (Child, Adult, Older Adult)
  • Outcome measures - Complete recovery from COVID-19 with resolution of symptoms|Admission to a hospital for further advanced treatment
NCT04621149 An Outpatient Study Investigating Non-prescription Treatments for COVID-19 Recruiting Phase 2 Nov/15/2020 Mar/31/2021
  • Alternative id - Profact-01
  • Interventions - Other: chlorine dioxide|Dietary Supplement: zinc acetate|Drug: Famotidine|Other: placebo|Dietary Supplement: lactoferrin, green tea extract
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - AZ Good Health Center, Tempe, Arizona, United States
  • Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 120
  • Age - 20 Years to 70 Years   (Adult, Older Adult)
  • Outcome measures - Reduction in Participant Symptoms of COVID-19|Incidence of Treatment-Emergent Adverse Events|Rate of Hospitalization|Change in Oxygen Saturation|Change in Body Temperature
NCT04333654 Hydroxychloroquine in Outpatient Adults With COVID-19 Terminated Phase 1 Apr/12/2020 May/26/2020
  • Alternative id - EFC16855|2020-001269-35|U1111-1249-6168
  • Interventions - Drug: Hydroxychloroquine SAR321068|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Investigational Site Number 8400001, Boston, Massachusetts, United States|Investigational Site Number 0561001, Bruxelles, Belgium|Investigational Site Number 0561002, Lodelinsart, Belgium|Investigational Site Number 2501001, Bordeaux Cedex, France|Investigational Site Number 2501002, Paris, France|Investigational Site Number 5281001, Groningen, Netherlands|Investigational Site Number 5281002, Harderwijk, Netherlands
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 8
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - Change from baseline to Day 3 in nasopharyngeal SARS-CoV-2 viral load (if quantitative PCR is available)|Number of participants by PCR result status (positive or negative) (if quantitative PCR is not available)|Change from baseline to Day 5 in nasopharyngeal SARS-CoV-2 viral load|Number of participants by PCR result status (positive or negative)|Number of participants with COVID-19 symptoms by severity|Time to resolution of COVID-19 Symptoms|Time to resolution of fever|Percentage of participants with resolution of fever|Percentage of participants hospitalized|Number of participants with Adverse Events
NCT04372628 Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19 Active, not recruiting Phase 2 Jun/01/2020 Jun/01/2022
  • Alternative id - 200827
  • Interventions - Drug: Lopinavir/Ritonavir 400 mg/100 mg|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University of Colorado School of Medicine, Aurora, Colorado, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Intermountain, Murray, Utah, United States|University of Wisconsin, Madison, Wisconsin, United States
  • Study designs - Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 600
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Modified COVID Ordinal Outcomes Scale: Study Day 15|Modified COVID Ordinal Outcome Scale: Study Day 8|Modified COVID Ordinal Outcome Scale: Study Day 29|Proportion of patients hospitalized: Day 1 to 29|Time to hospitalization Day 1 to Day 29|Time to symptom resolution: Day 1 to Day 29|All-cause, all-location mortality: Day 1 to Day 29|Oxygen-free days: Day 1 to Day 29|Fever-free days: Day 1 to Day 29|Ventilator-free days: Day 1 to Day 29|ICU-free days: Day 1 to Day 29|Hospital-free days: Day 1 to Day 29
NCT04709328 To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19 Not yet recruiting Phase 2|Phase 3 Mar/28/2021 Mar/01/2022
  • Alternative id - SCTA01-A301
  • Interventions - Drug: SCTA01|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations -
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 690
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Proportion of participants who experience COVID-19 related hospitalization (defined as at least 24 hours of acute care) or death (all cause) up to Day 29.|Time to sustained resolution of all COVID-19-related symptoms|- Change in symptom score (total of ratings)|Time to symptom improvement;|Proportion of participants admitted to hospital due to COVID-19|Proportion of participants with ≥1 COVID-19 related hospitalization|Proportion of participants with ≥2 COVID-19 related hospitalizations|Total number of COVID-19 related hospitalization|Proportion of participants who experience COVID-19 related emergency room (ER) visit|Proportion of participants with ≥1 ER visit due to COVID-19|Proportion of participants with ≥2 ER visits due to COVID-19 through Day 29|Proportion of participants admitted to an intensive care unit (ICU) due to COVID-19|Proportion of patients with all-cause mortality|Proportion of participants with O2 requirement|Proportion of participants with ventilation requirements|Proportion of participants that achieve SARS-CoV-2 clearance in nasopharyngeal (NP) or oropharyngeal (OP) samples|Change from baseline (Day 1) to Day 8 or Day 15 in SARS-CoV-2 viral shedding as measured by quantitative reverse transcription polymerase chain reaction (RT-qPCR) in NP or OP samples for SARS-CoV-2 test.|Cumulative incidence of serious adverse events (SAEs)|Cumulative incidence of Grade 1, 2, 3 and 4 adverse events (AEs)|Discontinuation or temporary suspension of infusions (for any reason)|Number and proportion of patients with ADE|Mean concentration-time profiles of SCTA01|Incidence and titers (if applicable) of anti-drug antibodies (ADA) to SCTA01
NCT04834115 Efficacy of Ivermectin in Outpatients With Non-severe COVID-19 Recruiting Phase 3 Nov/17/2020 May/30/2021
  • Alternative id - PINV20-387
  • Interventions - Drug: Ivermectin Tablets|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Facultad de Ciencias Médicas - Universidad Nacional de Asunción, Asunción, Paraguay
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 400
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Proportion of patients with hospitalization criteria|Proportion of patients with COVID-19 signs and symptoms|Proportion of cohabitants who had COVID-19 after the index case|Drug-related adverse events|Levels of IgG for SARS-CoV-2
NCT04510194 COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19) Active, not recruiting Phase 3 Jan/01/2021 Feb/01/2023
  • Alternative id - GIM-2020-29324
  • Interventions - Drug: Metformin|Drug: Placebo|Drug: Fluvoxamine|Drug: Ivermectin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Olive View UCLA Medical Center, Sylmar, California, United States|University of Colorado Denver; Department of Medicine; Anschutz Health and Wellness Center, Aurora, Colorado, United States|New West Physicians, Golden, Colorado, United States|Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States|American Health Network of Indiana, Greenfield, Indiana, United States|Hennepin County Medical Center, Minneapolis, Minnesota, United States|University of Minnesota, Minneapolis, Minnesota, United States
  • Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 1350
  • Age - 30 Years to 85 Years   (Adult, Older Adult)
  • Outcome measures - Clinical Progression|Maximum symptom severity|Clinical Progression Scale|Time to meaningful recovery|Laboratory Outcome Subsidy - Viral Load|Laboratory Outcome Subsidy|Laboratory Outcome Subsidy - Microbiome|Portion of participants with Post-Acute Sequelae of SARS-CoV-2 infection (PASC)
NCT04906694 Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (US) Completed Phase 2 Nov/16/2021 Jan/13/2022
  • Alternative id - DRP-COV-201US
  • Interventions - Biological: COVI-DROPS|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Future Innovative Treatments, LLC, Colorado Springs, Colorado, United States|Clinical Neuroscience dba CNS Healthcare, Jacksonville, Florida, United States|Med-Care Research, Miami, Florida, United States|Clinical Neuroscience Solutions Healthcare, Orlando, Florida, United States|Precision Research Center, Tampa, Florida, United States|Clinical Site Partners, Inc, Winter Park, Florida, United States|Randomize Now, Peachtree City, Georgia, United States|Revival Research Institute, Dearborn, Michigan, United States|Quality Clinical Research, Omaha, Nebraska, United States|Remington Davis, Columbus, Ohio, United States|Cyn3rgy Research, Gresham, Oregon, United States|WR-ClinSearch, Chattanooga, Tennessee, United States|Advanced Medical Trials, Georgetown, Texas, United States|Precision Comprehensive Clinical Research Solutions, Grapevine, Texas, United States|Centex Studies Inc. Houston, Houston, Texas, United States|LinQ, Pearland, Texas, United States|Epic Research, Red Oak, Texas, United States|Infectious Diseases Associates of Central Virginia, Lynchburg, Virginia, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 97
  • Age - 18 Years to 55 Years   (Adult)
  • Outcome measures - Proportion of subjects who have COVID-19-related visit or hospitalization|Proportion of subjects alive and free of hospitalization ˃ 24h duration for acute COVID-19 illness management through D29|Viral load change from baseline to D8|Change in WHO Clinical Progression Scale score|Viral load change from baseline to D29
NCT05222425 Treatment of Non-severe Covid-19 Outpatients With Xagrotin, Phase 3 Not yet recruiting Phase 3 Jun/01/2022 Dec/07/2022
  • Alternative id - 03-022022-FA3XAG/NO
  • Interventions - Drug: Xagrotin|Drug: Green tea
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Directorate of health of Sulaimani, Iraq -KRG, Sulaymaniyah, Iraq
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 3000
  • Age - 18 Years to 99 Years   (Adult, Older Adult)
  • Outcome measures - Mortality|Duration of Disease From Beginning of Treatment|Hospitalization|Duration of Hospitalization When Occurred
NCT04784481 Ivermectin Reproposing for Mild Stage COVID-19 Outpatients Completed Phase 1|Phase 2 Sep/20/2020 Jan/18/2021
  • Alternative id - 5077-410-CH2020
  • Interventions - Drug: Ivermectin
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - SI.PRO.SA, Ministerio de Salud Pública, Tucumán, Argentina
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 254
  • Age - 18 Years to 75 Years   (Adult, Older Adult)
  • Outcome measures - Proportion test|Odd Ratio|Odd Ratio and logistic regression test
NCT04662073 COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol Active, not recruiting Phase 2 Apr/23/2021 Aug/01/2022
  • Alternative id - COPPS-Camostat
  • Interventions - Drug: Camostat|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - ValleyCare Medical Center, Pleasanton, California, United States|Stanford University, Stanford, California, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 120
  • Age - 18 Years to 80 Years   (Adult, Older Adult)
  • Outcome measures - For the Viral Domain: Change in Viral Shedding|For Clinical Domain: Time-to-sustained-resolution|Time to viral cessation|Time to first resolution|Time to full resolution|Indicator of SARS-CoV-2 related hospitalizations, ED visits, or death in outpatients with COVID-19 disease.|Indicator participant has developed antibodies to SARS-CoV-2|Indicator participant has a negative SARS-CoV2 RT-PCR test
NCT04332107 Azithromycin for COVID-19 Treatment in Outpatients Nationwide Terminated Phase 3 May/22/2020 Mar/30/2021
  • Alternative id - 20-30504
  • Interventions - Drug: Azithromycin|Drug: Placebos
  • Study type - Interventional
  • Study results - Has Results
  • Locations - University of California San Francisco, San Francisco, California, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 263
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of Participants Who Were Symptom Free at Day 14|Viral Load|Mortality|Adverse Events|Positive SARS-CoV-2 Test - Nasal Swab|Positive SARS-CoV-2 Test - Saliva Swab|Positive SARS-CoV-2 Test - Rectal Swab|Genetic Macrolide Resistance Determinants|Secondary Outcomes Through Day 21|Number of Participants With Emergency Room Visits|Number of Household Members With COVID-19 (Confirmed or Symptomatic)|Number of Participants That Died|Number of Participants Reporting Hospitalization
NCT04910269 Outpatient Treatment With Anti-Coronavirus Immunoglobulin Recruiting Phase 3 Aug/06/2021 Aug/01/2023
  • Alternative id - INSIGHT12|2021-001663-24
  • Interventions - Biological: Hyperimmune immunoglobulin to SARS-CoV-2 (hIVIG)|Other: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - MedStar Health Research Institute, Washington, District of Columbia, United States|Washington DC Veterans Affairs Medical Center, Washington, District of Columbia, United States|University of Maryland Medical System, Baltimore, Maryland, United States|Infusion Associates, Grand Rapids, Michigan, United States|Mount Sinai Beth Israel Hospital, New York, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Hendrick Medical Center, Abilene, Texas, United States|CHRISTUS Spohn Shoreline Hospital, Corpus Christi, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Swedish Hospital First Hill, Seattle, Washington, United States|Odense University Hospital, Odense, C, Denmark|Aarhus Universitetshospital, Skejby, Aarhus, N, Denmark|Department of Infectious Diseases, Aalborg, Denmark|Rigshospitalet, CHIP, Copenhagen, Denmark|Herlev/Gentofte Hospital, Hellerup, Denmark|Hvidovre University Hospital, Department of Infectious Diseases, Hvidovre, Denmark|Kolding Sygehus, Kolding, Denmark|Dept of Critical Care and Pulmonary Medicine, Evangelismos General Hospital, Athens, Attica, Greece|3rd Dept of Medicine, Medical School, Athens, Attica, Greece|4th Department of Internal Medicine, Athens, Attica, Greece|Hospital General Dr. Manuel Gea Gonzáles, Mexico City, Cdmx, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Cdmx, Mexico|Instituto Nacional de Enfermedades Respiratorias Ismael Cosió Villegas, Mexico City, Cdmx, Mexico|CHRISTUS Centro de Excelencia en Investigacion (Obispado), Monterrey, NL, Mexico|Hospital General Dr. Aurelio Valdivieso, Oaxaca City, OA, Mexico|Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|CAP Can Bou, Castelldefels, Barcelona, Spain|CAP El Maresme, Mataro, Barcelona, Spain
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  • Enrollment - 820
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Clinical Status|All-cause hospitalization or death through 28 days.|All-cause mortality through 28 days.|Significant Disease Progression|Ordinal Scale Distribution|Disease Progression Through 7 Days|Significant Disease Progression Through 7 Days|Disease Progression at Follow-up|Activity Limitations at Follow-up|Change in Viral Burden from Serum Antigen|Change in Viral Burden from PCR|Change in SARS-CoV-2 Antibody Concentration|Healthcare Utilization at Follow-up|Worst Status Through 28 Days|Hypoxemia Through Day 7|Additional COVID-19 Treatment
NCT04660422 Advance Care Planning: Communicating With Outpatients for Vital Informed Decision Completed Dec/15/2020 Dec/31/2021
  • Alternative id - 20-600|UH3AG060626-03S1
  • Interventions - Other: VitalTalk communication skills training|Other: ACP Decisions Video Program|Other: Intervention training:|Other: Medical Record Review
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Northwell Health, New Hyde Park, New York, United States
  • Study designs - Observational Model: Cohort|Time Perspective: Other
  • Enrollment - 42019
  • Age - 65 Years and older   (Older Adult)
  • Outcome measures - Rate for Advanced Care Planning (ACP) documentation|Rate of orders for resuscitation preferences|Rate of palliative care consultation|Rate of referral to hospice|Advanced Care Planning (ACP) documentation rates among under-represented minority groups.
NCT04331899 Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19 Completed Phase 2 Apr/25/2020 May/06/2021
  • Alternative id - 55619
  • Interventions - Drug: Peginterferon Lambda-1a|Other: Placebo
  • Study type - Interventional
  • Study results - Has Results
  • Locations - Stanford University School of Medicine, Stanford, California, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
  • Enrollment - 120
  • Age - 18 Years to 75 Years   (Adult, Older Adult)
  • Outcome measures - Duration Until Viral Shedding Cessation|Change in Sars-CoV-2 Viral Load|Area Under the Curve of SARS-COV-2 Viral Load|Duration Until Resolution of Symptoms|Count of Participants Requiring Emergency Department Visits or Hospitalizations Within 28 Days of Initiation of Treatment
NCT04369807 Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection Active, not recruiting Apr/21/2020 May/31/2023
  • Alternative id - 20/SC/0185
  • Interventions - Diagnostic Test: Outpatient MRI
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Mayo Clinic Healthcare, London, United Kingdom|Gemini, Oxford, United Kingdom
  • Study designs - Observational Model: Cohort|Time Perspective: Prospective
  • Enrollment - 507
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Characterise prevalence and severity of organ volume change and damage (heart, kidneys and liver)|Characterise prevalence and severity of organ volume change and damage (lung, pancreas and spleen)|Change from Baseline in liver-specific biomarkers: volume, iron corrected T1(cT1), fat content and T2star|Change from Baseline in organ-specific biomarkers characterising organ volume change in the heart and spleen along with organ volume and damage in the kidney, liver and pancreas assessed by volume, iron corrected T1 (cT1) and fat infiltration|Change in patient reported outcome measured by the Dyspnea-12 questionnaire|Change in patient reported outcome measured by the Saint George's Respiratory questionnaire (SGRQ)|Change in patient reported outcome measured by the EQ-5D-5L questionnaire|Degree of change in liver MR-derived biomarkers
NCT04435795 Inhaled Ciclesonide for Outpatients With COVID19 Terminated Phase 2|Phase 3 Sep/14/2020 Jul/08/2021
  • Alternative id - 2021-6696
  • Interventions - Drug: Normal Saline intranasal and placebo inhaler|Drug: Ciclesonide|Drug: Ciclesonide nasal
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University of British Columbia, Vancouver, British Columbia, Canada|Sunnybrook Hospital, Toronto, Ontario, Canada|McGill University Health Center, Montreal, Quebec, Canada
  • Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  • Enrollment - 215
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Proportion of participants with no symptoms of cough, fever or dyspnea|Overall feeling|Improvement in dyspnea|Visual Analog scale for Cough|Hospitalization for SARS-CoV-2|Changes in Promis dyspnea characteristics scale|Change in dyspnea severity Promis scale|Incidence of new oxygen use|Mortality|Anxiety|Sleep Disturbance
NCT04621461 Placebo Controlled Trial to Evaluate Zinc for the Treatment of COVID-19 in the Outpatient Setting Completed Phase 4 Dec/20/2020 Feb/08/2021
  • Alternative id - 20-19
  • Interventions - Dietary Supplement: Zinc Sulfate 220 MG|Drug: Placebo
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - St. Francis Hospital - The Heart Center, Roslyn, New York, United States
  • Study designs - Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 3
  • Age - 30 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of participants hospitalized and/or requiring repeat emergency room visits|Number of participants admitted to the Intensive care unit (ICU)|Number of participants on a ventilator|All-cause mortality|Time to resolution of COVID-19 symptoms|Severity of symptoms
NCT04471636 Telemedicine in Outpatient Covid-19 Patients Recruiting Not Applicable Sep/18/2020 Dec/01/2021
  • Alternative id - 20-448
  • Interventions - Device: Withings ScanWatch
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - LMU Klinikum, Munich, BY, Germany
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 600
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Rate of participants with a combination of hospitalization and unplanned use of hospital emergency department or emergency medical service|Rate of participants hospitalized|Rate of participants with unplanned use of hospital emergency department or emergency medical service|Rate of participants experiencing death of any cause|Rate of participants experiencing death of Covid-19
NCT05021575 Effects of COVID-19 Pandemic on a Health Care System: Case Study of the CirculatORy System in LiThuania Completed Jun/01/2020 Dec/31/2020
  • Alternative id - S-COV-20-27|2020/8-1247-730
  • Interventions - Other: Data collection on outpatient care|Other: Data collection on hospitalisation|Other: Data collection on cardiovascular mortality|Other: Data collection of patients presenting to the tertiary care centre with acute coronary syndrome
  • Study type - Observational
  • Study results - No Results Available
  • Locations - Institute of Hygiene, Vilnius, Lithuania|National Health Insurance Fund under the Ministry of Health, Lithuania, Vilnius, Lithuania|Vilnius University, Vilnius, Lithuania
  • Study designs - Observational Model: Cohort|Time Perspective: Retrospective
  • Enrollment - 839678
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of outpatient care visits for cardiovascular reasons in Lithuania in 2019 and 2020|Number of cardiovascular hospitalisations in Lithuania in 2019 and 2020|Cardiovascular mortality rates in Lithuania in 2019 and 2020|Evaluation of sex and age differences in changes of CV care provision and CV deaths during the pandemic and comparison between 2019 and 2020|In-hospital mortality rates in Lithuania in 2019 and 2020|Comparison of distribution of death places in Lithuania in 2019 and 2020|Comparison of all-cause mortality during the hospital stay and at 3 months of follow-up in patients presenting to a tertiary care centre with acute coronary syndrome during the first quarantine in 2020 and in a corresponding period of 2019
NCT04508023 A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection Recruiting Phase 3 Aug/13/2020 May/19/2022
  • Alternative id - CR108849|39039039DVT3004
  • Interventions - Drug: Rivaroxaban|Other: Placebo|Other: Standard of Care (SOC)
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - University of Arizona, Tucson, Arizona, United States|Southern California Permanente Medical Group, Los Angeles, California, United States|Kaiser Permanente Northern California, Oakland, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Florida Hospital Orlando, Orlando, Florida, United States|Emory University, Atlanta, Georgia, United States|Morehouse School of Medicine, Atlanta, Georgia, United States|Atlanta VA Medical Center, Decatur, Georgia, United States|Northshore Universite Healthsystem, Evanston, Illinois, United States|Meritus Center for Clinical Research, Hagerstown, Maryland, United States|Brigham & Women's Hospital, Boston, Massachusetts, United States|Henry Ford Hospital, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Lenox Hill Hospital -Northwell Health, New York, New York, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Health Physicians Group, Fort Worth, Texas, United States|Franciscan Research Center, Tacoma, Washington, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  • Enrollment - 4000
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Time to First Occurrence of a Composite Endpoint of Symptomatic VTE, MI, Ischemic Stroke, Acute Limb Ischemia, Non-CNS Systemic Embolization, All-cause Hospitalization and All-cause Mortality|Time to First Occurrence of a Composite Endpoint of Symptomatic VTE, MI, Ischemic Stroke, Acute Limb Ischemia, Non-CNS Systemic Embolization, and All-cause Mortality|Time to First Occurrence of All-cause Hospitalization|Time to First Occurrence of Symptomatic VTE|Time to First Occurrence of an Emergency Room (ER) Visit|Time to First Occurrence of Symptomatic VTE, MI, Ischemic Stroke, Acute Limb Ischemia, Non-CNS Systemic Embolization, and All-cause Hospitalization|Percentage of Participants who are Hospitalized or Dead From Any Cause|Time to All-cause Mortality up to Day 35|Time to First Occurrence of International Society on Thrombosis and Hemostasis (ISTH) Critical Site and Fatal Bleeding|Time to First Occurrence of ISTH Major Bleeding Events|Time to First Occurrence of Clinically Relevant Non-major Bleeding
NCT04360759 Chloroquine Outpatient Treatment Evaluation for HIV-Covid-19 Withdrawn Phase 3 May/01/2020 Jun/30/2021
  • Alternative id - HIV-COVID-19 CQOTE
  • Interventions - Drug: Chloroquine or hydroxychloroquine
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Khayelitsha Hospital, Cape Town, Western Cape, South Africa|Groote Schuur Hospital, Cape Town, Western Cape, South Africa
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 0
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Event-free survival at 28 days post-randomization between experimental group and standard of care group|Incidence of serious adverse events|Incidence of adverse events of special interest related to investigational product at time of hospitalisation|Premature discontinuation of treatment|Time from treatment initiation to death, ARDS (PF/SF ratio < 300), or mechanical ventilation|Proportion with moderate and severe ARDS|Duration of hospitalisation and ICU stay in survivors|Incidence of Covid-19 in household contacts
NCT04414124 A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19 Completed Not Applicable Aug/02/2020 Feb/02/2021
  • Alternative id - K031-120
  • Interventions - Other: KB109 + Self Supportive Care (SSC)|Other: Self Supportive Care (SSC) Alone
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Healthstar Research, Hot Springs, Arkansas, United States|Axon Clinical Research, Riverside, California, United States|Medical Center for Clinical Research, San Diego, California, United States|Vista Health Research, Miami, Florida, United States|Bio-Medical Research, Miami, Florida, United States|Mount Vernon Clinical Research, Atlanta, Georgia, United States|Centex Studies, Inc. - Lake Charles, Lake Charles, Louisiana, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Wake Research - Clinical Research Center of Nevada, LLC, Las Vegas, Nevada, United States|Carolina Institute For Clinical Research, Fayetteville, North Carolina, United States|M3 Wake Research, Inc, Raleigh, North Carolina, United States|TruCare Internal Medicine and Infectious Diseases, DuBois, Pennsylvania, United States|ClinSearch LLC, Chattanooga, Tennessee, United States|Global Medical Research, DeSoto, Texas, United States|Centex Studies, Houston, Texas, United States|Infectious Diseases Associates of Central Virginia, Lynchburg, Virginia, United States
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other
  • Enrollment - 350
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - Number of patients experiencing study-product related treatment-emergent adverse events (TEAEs)|Change from baseline to end of intake in overall composite COVID-19 symptom score|Time to resolution of fever|Proportion of patients with decreased oxygen saturation|Effect of COVID-19 symptoms on physical activities|Proportion of patients requiring hospitalization|Time to resolution of overall 13 COVID-19 related symptoms.|Time to resolution of overall 8 cardinal COVID-19 related symptoms.
NCT04657471 Hospitalization or Outpatient ManagEment of Patients With SRAS-CoV-2 Infection - Revised HOME-CoV Score Study Completed Not Applicable Dec/08/2020 Mar/08/2021
  • Alternative id - 2020-A03067-32
  • Interventions - Other: revised HOME-CoV score
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - CHU Angers, Angers, France
  • Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 1300
  • Age - 18 Years and older   (Adult, Older Adult)
  • Outcome measures - The safety of the revised HOME-CoV score strategy for home treatment|The efficacy of the revised HOME-CoV score strategy for home treatment|The applicability of the revised HOME-CoV score strategy for home treatment|The reliability of the revised HOME-CoV score strategy for home treatment|The predictive performances of the revised HOME-CoV score of evolution towards a COVID-19 with a WHO-OSCI≥5.|The predictive performances of the revised HOME-CoV score of evolution towards a COVID-19 with a WHO-OSCI≥6|The predictive performances of the revised HOME-CoV score of evolution towards a fatal COVID-19|Subgroup analysis in patients with confirmed COVID-19 (positive SARS-CoV2 RT-PCR) of the predictive performances of the revised HOME-CoV score|The predictive performances of the revised HOME-CoV score as compared to those of other prognostic scores for COVID-19|Venous thrombo-embolism in COVID-19 patients (ancillary study)
NCT04356495 Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation Completed Phase 2|Phase 3 Jul/29/2020 Oct/22/2021
  • Alternative id - CHUBX 2020/12
  • Interventions - Dietary Supplement: Vitamins|Drug: Telmisartan|Drug: Ciclesonide|Drug: interferon β-1b
  • Study type - Interventional
  • Study results - No Results Available
  • Locations - Bordeaux university Hospital, Bordeaux, France|CHU de Dijon-Bourgogne, Dijon, France|CHU de Montpellier, Montpellier, France|CHRU de Nancy, Nancy, France|Groupe hospitalier Paris Saint Joseph, Paris, France|CNGE, Paris, France|CHU de Toulouse, Toulouse, France
  • Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  • Enrollment - 412
  • Age - 50 Years and older   (Adult, Older Adult)
  • Outcome measures - Pilot Phase: Proportion of participants who had a Grade 3 or 4 adverse event|Efficacy phase: Death|Efficacy phase: oxygen therapy|Efficacy phase: hospitalization|Proportion of hospitalizations, overall and by cause, in each group|Death and causes of death|Proportion of intensive care hospitalizations, overall and by cause, in each group|Proportion of participants with negative SARS-CoV-2 RT-PCR|Haematological markers evolution|Inflammatory markers evolution|Adverse events|Adverse reactions|Acceptability of the treatment|Antibiotic consumption|Oxygen saturation worsening|protocol follow-up